Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/05—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
  • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/18—Feminine contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
  • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
  • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
  • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
  • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
  • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
  • C07D243/24—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

• the present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use.
• the present invention provides benzodiazepine derivatives and structurally and functionally related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproriferation, vascular abnormalities, and the like.
• Multicellular organisms exert precise control over cell number. A balance between cell proliferation and cell death achieves this homeostasis. Cell death occurs in nearly every type of vertebrate cell via necrosis or through a suicidal form of cell death, known as apoptosis. Apoptosis is triggered by a variety of extracellular and intracellular signals that engage a common, genetically programmed death mechanism.
• Multicellular organisms use apoptosis to instruct damaged or unnecessary cells to destroy themselves for the good of the organism. Control of the apoptotic process therefore is very important to normal development, for example, fetal development of fingers and toes requires the controlled removal, by apoptosis, of excess interconnecting tissues, as does the formation of neural synapses within the brain. Similarly, controlled apoptosis is responsible for the sloughing off of the inner lining of the uterus (the endometrium) at the start of menstruation. While apoptosis plays an important role in tissue sculpting and normal cellular maintenance, it is also the primary defense against cells and invaders (e.g. , viruses) which threaten the well being of the organism.
• invaders e.g. , viruses
• effector cells e.g., cytotoxic T lymphocytes "CTLs" destroy virus-infected cells by inducing the infected cells to undergo apoptosis.
• CTLs cytotoxic T lymphocytes
• the organism subsequently relies on the apoptotic process to destroy the effector cells when they are no longer needed.
• Autoimmunity is normally prevented by the CTLs inducing apoptosis in each other and even in themselves. Defects in this process are associated with a variety of autoimmune diseases such as lupus erythematosus and rheumatoid arthritis.
• Multicellular organisms also use apoptosis to instruct cells with damaged nucleic acids (e.g., DNA) to destroy themselves prior to becoming cancerous.
• Some cancer-causing viruses overcome this safeguard by reprogramming infected (transformed) cells to abort the normal apoptotic process.
• HPVs human papilloma viruses
• E6 protein which inactivates the p53 apoptosis promoter.
• Epstein-Barr virus the causative agent of mononucleosis and Burkitt's lymphoma, repro grams infected cells to produce proteins that prevent normal apoptotic removal of the aberrant cells thus allowing the cancerous cells to proliferate and to spread throughout the organism.
• HIV human immunodeficiency virus
• Some cancers that arise by non- viral means have also developed mechanisms to escape destruction by apoptosis.
• Melanoma cells for instance, avoid apoptosis by inhibiting the expression of the gene encoding Apaf-1.
• Other cancer cells especially lung and colon cancer cells, secrete high levels of soluble decoy molecules that inhibit the initiation of CTL mediated clearance of aberrant cells.
• Faulty regulation of the apoptotic machinery has also been implicated in various degenerative conditions and vascular diseases. It is apparent that the controlled regulation of the apoptotic process and its cellular machinery is vital to the survival of multicellular organisms. Typically, the biochemical changes that occur in a cell instructed to undergo apoptosis occur in an orderly procession. However, as shown above, flawed regulation of apoptosis can cause serious deleterious effects in the organism.
• cytotoxic agents have widespread utility in both human and animal health and represent the first line of treatment for nearly all forms of cancer and hyperproliferative autoimmune disorders like lupus erythematosus and rheumatoid arthritis.
• cytotoxic agents in clinical use exert their effect by damaging DNA (e.g., cis- diaminodichroplatanim(II) cross-links DNA, whereas bleomycin induces strand cleavage).
• DNA e.g., cis- diaminodichroplatanim(II) cross-links DNA, whereas bleomycin induces strand cleavage.
• the result of this nuclear damage if recognized by cellular factors like the p53 system, is to initiate an apoptotic cascade leading to the death of the damaged cell.
• cytotoxic chemotherapeutic agents have serious drawbacks. For example, many known cytotoxic agents show little discrimination between healthy and diseased cells. This lack of specificity often results in severe side effects that can limit efficacy and/or result in early mortality. Moreover, prolonged administration of many existing cytotoxic agents results in the expression of resistance genes (e.g., bcl-2 family or multi-drug resistance (MDR) proteins) that render further dosing either less effective or useless. Some cytotoxic agents induce mutations into p53 and related proteins. Based on these considerations, ideal cytotoxic drugs should only kill diseased cells and not be susceptible to chemo-resistance.
• resistance genes e.g., bcl-2 family or multi-drug resistance (MDR) proteins
• One strategy to selectively kill diseased cells or block their growth is to develop drugs that selectively recognize molecules expressed in diseased cells.
• effective cytotoxic chemotherapeutic agents would recognize disease indicative molecules and induce (e.g., either directly or indirectly) the death of the diseased cell.
• markers on some types of cancer cells have been identified and targeted with therapeutic antibodies and small molecules, unique traits for diagnostic and therapeutic exploitation are not known for most cancers.
• specific molecular targets for drug development have not been identified. What are needed are improved compositions and methods for regulating the apoptotic processes in subjects afflicted with diseases and conditions characterized by faulty regulation of these processes (e.g., viral infections, hyperproliferative autoimmune disorders, chronic inflammatory conditions, and cancers).
• the present invention provides novel compounds that find use in treating a number of diseases and conditions in humans and animals and that find use in research, compound screening, and diagnostic applications.
• the present invention also provides uses of these novel compounds, as well as the use of known compounds, that elicit particular biological responses (e.g., compounds that bind to particular target molecules and/or cause particular cellular events).
• Such compounds and uses are described throughout the present application and represent a diverse collection of compositions and applications.
• compositions and uses are described below. The present invention is not limited to these particular compositions and uses.
• composition comprising the following formula:
• Rl comprises a chemical moiety comprising a hydrogen bonding proton donor (e-g., a hydroxyl group, a phenol group, an amide group, a sulfonamide group, an amine group, an aniline group, a benzimidizalone group, a carbamate group, and an imidizole group); and R2 comprises a hydrophobic chemical moiety.
• Rl is selected from the group consisting of:
• Rl ', R2, R3 and R4 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the ' aliphatic chain terminates with a carboxylic acid subgroup; a
• R2 is selected from group consisting of: napthalalanine
• R2 comprises an aryl group. In other preferred embodiments, R2 comprises an aliphatic group.
• Rl is selected from the group consisting of:
• composition comprises the following formula:
• R3 is selected from the group consisting of hydrogen, amino, a linear or branched, saturated or unsaturated, substituted (e.g., substituted with amines, esters, amides or phosphatases) or non-substituted, aliphatic chain having at least 2 carbons;
• R4 is selected from the group consisting of H, a ketone, and a nitrogen; and R5 is selected from H, a hydroxy, an alkoxy, a carboxylic acid, a carboxylic ester, a halogen, a nitro, a sulfonamide, an amide, a carbamate, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NO 2 ; SR'; and NR' 2 , wherein R' is defined as a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated
• the compound is selected from the group consisting of:
• composition is described by:
• WW, XX, YY and ZZ are present or absent, and are selected from the group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri- substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, NHSO 2 alkyl; and wherein Z is selected from the group consisting of SO 2 Ar
• R5 is selected from the group consisting of alkyl, mono-substituted alkyl, di-substituted alkyl, and tri- substituted alkyl.
• composition is described by:
• R2 is selected from the group consisting of
• R3 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, carboxylic acid, amide, SO 2 NH 2 , NHSO 2 alkyl, and NO 2 ; wherein BB, CC, DD, and R4 are present or absent, and are selected from the group consisting of hydrogen, CF 3 , NO 2 , alkyl, halogen, OH, O-alkyl, nitro, OCH 2 CH 2 OH, SO 2 H, mono-substituted alkyl, di- substituted alkyl, tri-substituted alkyl, CO 2 H, heterocycle, SO 2 NH 2 , SO 2 NH-alkyl,
• R5 is selected from the group consisting OfNHSO 2 , CH 2 NHSO 2 , CH 2 CH 2 NHSO 2 , CH 2 CH 2 CH 2 NHSO 2 , SO 2 NH, SO 2 NHCH 2 , SO 2 NHCH 2 CH 2 , SO 2 NHCH 2 CH 2 , CH 2 , CH 2 CH 2 , CH 2 CH 2 CH 2 , SO 2 , CH 2 SO, SOCH 2 , OCH 2 CH 2 O, SO, CH 2 CH 2 SO, and SOCH 2 CH 2 .
• the composition is selected from the group consisting of:
• the present invention provides a method of treating cells, comprising a) providing i) target cells; and ii) a composition comprising the following formula:
• Rl comprises a chemical moiety comprising a hydrogen bonding proton donor (e.g., a hydroxyl group, a phenol group, an amide group, a sulfonamide group, an amine group, an aniline group, a benzimidizalone group, a carbamate group, and an imidizole group); and R2 comprises a hydrophobic chemical moiety; and b) exposing said target cells to said composition under conditions such that said composition binds to said mitochondria so as to increase superoxide levels or alter cellular ATP levels in said cells.
• a hydrogen bonding proton donor e.g., a hydroxyl group, a phenol group, an amide group, a sulfonamide group, an amine group, an aniline group, a benzimidizalone group, a carbamate group, and an imidizole group
• R2 comprises a hydrophobic chemical moiety
• the treating is selected from the group consisting of inducing cellular growth arrest in the target cells, inducing cellular death in the target cells, and inducing cellular apoptosis in the target cells, hi preferred embodiments, the target cells are in a subject having, for example, an autoimmune disorder, a hyproliferative disorder, an epidermal hyperplasia disorder, a pigment disorder, a cardiovascular disorder, and/or a viral disorder.
• composition is selected from the group consisting of:
• the target cells are selected from the group consisting of in vitro cells, in vivo cells, and ex vivo cells. In other preferred embodiments, the target cells are cancer cells. In still other preferred embodiments, the target cells are selected from the group consisting of B cells, T cells, and granulocytes.
• Rl is selected from the group consisting of:
• Rl', R2, R3 and R4 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid subgroup; a linear or branche
• R2 is selected from group consisting of: napthalalanine
• n 0-5; ll regioisomers) .
• R2 comprises an aryl group. In other preferred embodiments, R2 comprises an aliphatic group. In some preferred embodiments, Rl is selected from the group consisting of:
• composition comprises the following formula:
• R3 is selected from the group consisting of hydrogen, amino, a linear or branched, saturated or unsaturated, substituted (e.g., substituted with amines, esters, amides or phosphatases) or non-substituted, aliphatic chain having at least 2 carbons;
• R4 is selected from the group consisting of H, a ketone, and a nitrogen;
• R5 is selected from H, a hydroxy, an alkoxy, a carboxylic acid, a carboxylic ester, a halogen, a nitro, a sulfonamide, an amide, a carbamate, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted
• X is selected from the group consisting of
• WW, XX, YY and ZZ are present or absent, and are selected from the group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri- substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, NHSO 2 alkyl; and wherein Z is selected from the group consisting of
• R5 is selected from the group consisting of alkyl, mono-substituted alkyl, di-substituted alkyl, and tri-substituted alkyl.
• the composition is described by:
• R2 is selected from the group consisting of
• R3 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, carboxylic acid, amide, SO 2 NH 2 , NHSO 2 alkyl, and NO 2 ; wherein BB, CC, DD, and R4 are present or absent, and are selected from the group consisting of hydrogen, CF 3 , NO 2 , alkyl, halogen, OH 5 O-alkyl, nitro, OCH 2 CH 2 OH, SO 2 H, mono-substituted alkyl, di- substituted alkyl, tri-substituted alkyl, CO 2 H, heterocycle, SO 2 NH 2 , SO 2 NH-alkyl, NHSO 2 alkyl, methyl ester, propyl ester, and ethyl ester; and wherein R5 is selected from the group consisting OfNHSO 2 , CH 2 NHSO 2 , CH 2 CH 2 NHSO 2 , CH 2 CH 2 CH 2 NHSO 2 , SO 2 NH
• composition is selected from the group consisting of:
• the presen ,t invention Y provides a ph m ar d maceutical composition
• Rl comprises a chemical moiety comprising a hydrogen bonding proton donor (e.g., a hydroxyl group, a phenol group, an amide group, a sulfonamide group, an amine group, an aniline group, a benzimidizalone group, a carbamate group, and an imidizole group); and R2 comprises a hydrophobic chemical moiety.
• a hydrogen bonding proton donor e.g., a hydroxyl group, a phenol group, an amide group, a sulfonamide group, an amine group, an aniline group, a benzimidizalone group, a carbamate group, and an imidizole group
• R2 comprises a hydrophobic chemical moiety.
• the compound is selected from the group consisting of:
• Rl is selected from the group consisting of:
• Rl ', R2, R3 and R4 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid subgroup; a linear or
• R2 is selected from group consisting of: napthalalanine
• n 0-5; ll regioisomers) .
• R2 comprises an aryl group. In other preferred embodiments, R2 comprises an aliphatic group. In some preferred embodiments, Rl is selected from the group consisting of:
• composition comprises the following formula:
• R3 is selected from the group consisting of hydrogen, amino, a linear or branched, saturated or unsaturated, substituted (e.g., substituted with amines, esters, amides or phosphatases) or non-substituted, aliphatic chain having at least 2 carbons;
• R4 is selected from the group consisting of H, a ketone, and a nitrogen;
• R5 is selected from H, a hydroxy, an alkoxy, a carboxylic acid, a carboxylic ester, a halogen, a nitro, a sulfonamide, an amide, a carbamate, an amino, a lower- alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted
• composition is described by:
• X is selected from the group consisting of
• WW, XX, YY and ZZ are present or absent, and are selected from the group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri- substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, NHSO 2 alkyl; and wherein Z is selected from the group consisting of _
• R5 is selected from the group consisting of alkyl, mono-substituted alkyl, di-substituted alkyl, and tri- substituted alkyl.
• R2 is selected from the group consisting of
• R3 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, carboxylic acid, amide, SO 2 NH 2 , NHSO 2 alkyl, and NO 2 ; wherein BB, CC, DD, and R4 are present or absent, and are selected from the group consisting of hydrogen, CF 3 , NO 2 , alkyl, halogen, OH, O-alkyl, nitro, OCH 2 CH 2 OH, SO 2 H, mono-substituted alkyl, di- substituted alkyl, tri-substituted alkyl, CO 2 H, heterocycle, SO 2 NH 2 , SO 2 NH-alkyl,
• R5 is selected from the group consisting OfNHSO 2 , CH 2 NHSO 2 , CH 2 CH 2 NHSO 2 , CH 2 CH 2 CH 2 NHSO 2 , SO 2 NH, SO 2 NHCH 2 , SO 2 NHCH 2 CH 2 , SO 2 NHCH 2 CH 2 , CH 2 , CH 2 CH 2 , CH 2 CH 2 CH 2 , SO 2 , CH 2 SO, SOCH 2 , OCH 2 CH 2 O, SO, CH 2 CH 2 SO, and SOCH 2 CH 2 -In preferred embodiments, the composition is selected from the group consisting of:
• the present invention provides a method of identifying therapeutic compositions, comprising a) providing a sample comprising mitochondrial F 1 F 0 - ATPase, and molecular modeling software; b) identifying a candidate F 1 F 0 -ATPaSe inhibitor with the molecular modeling software; c) contacting the inhibitor with the sample; d) measuring the kcat/Km of the mitochondrial F 1 F 0 -ATPaSe; and e) selecting the compositions that bind predominantly a F ⁇ o -ATPase-substrate complex and that do not alter the kcat/Km ratio of the mitochondrial F 1 F 0 -ATPaSe upon binding of the mitochondrial F 1 F 0 -ATPaSe as therapeutic compositions.
• the method further comprises the step off) testing the selected compositions in an animal to identify low toxicity and ability to treat an autoimmune disorder.
• the sample further comprises mitochondria.
• the F 1 F 0 -ATPaSe is a pure enzyme.
• the F 1 F 0 -ATPaSe is located in a sub-mitochondrial particle.
• the kcat/Km ratio is measured by determining the rate of ATP hydrolysis or synthesis as a function of ATP concentration and inhibitor concentration. In other preferred embodiments, the kcat/Km ratio is calculated from Km Vmax, and the enzyme concentration.
• the present invention provides a composition comprising the following formula:
• Rl is selected from the group consisting of:
• X is selected from the group consisting of heteroatom
• alkyl and substituted alkly; O 2 Ar .
• Z and Y are separately selected from the group consisting of O, N
• R3 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, carboxylic acid, amide SO 2 NH 2 , NHSO 2 alkyl, and NO 2 .
• Rl is a nitrogen atom or a carbon atom
• R2 is comprises a chemical moiety comprising a heterocyclic group containing 3 or more carbon atoms
• R3 comprises a chemical moiety comprising a heterocyclic group containing 3 or more carbon atoms
• R4 and R5 are separately selected from the group consisting of: hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety.
• the composition comprises the formula:
• R6 is selected from the group consisting of H and a ketone; and wherein R7 is selected from the group consisting of H and a ketone.
• composition comprises the formula:
• R8 is carbon or nitrogen and R9 is selected from H, a hydroxy, an alkoxy, a halogen, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NO 2 ; SR'; and NR' 2 , wherein R' is defined as a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxyl subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least at least
• the composition comprises the formula: wherein R9 is selected from H, a hydroxy, an alkoxy, a halo, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NO 2 ; SR'; and NR' 2 , wherein R' is defined as a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxyl subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least at least one
• the composition comprises the formula: wherein RlO is selected from the group consisting of: hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; and wherein R7 is selected from the group consisting of H and a ketone.
• R3 is selected from the group consisting of:
• R12, R13, R14 and R15 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid subgroup; a linear or branche
• R4 or R5 are selected from group consisting of:
• R4 or R5 is selected from the group consisting of: wherein Rl 6 is carbon or nitrogen; wherein Rl 7 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8 is carbon or nitrogen; wherein Rl 9 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; and
• R4 or R5 is wherein
• X is selected from the group consisting of , alkyl, substituted alkyl, sulfolamide, SO 2 alkyl, NHSO 2 , CH 2 , CH 2 CH 2 , SO 2 , CH 2 SO 2 , SO 2 CH 2 , OCH 2 CH 2 O, SO, CH 2 CH 2 SO, SOCH 2 CH 2 ; and wherein L, M and N are present or absent, and are selected from the group consisting of alkyl, NO 2 , halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, CF 3 , aniline, nitro, heterocycle, mono-substituted alkyl, di- substituted alkyl, and tri-substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, SOalkyl, NHSO 2 alkyl; wherein Y is selected from the group consisting of hydrogen, alkyl, substituted alkyl
• the composition is selected from the group consisting of:
• the present invention provides a composition comprising the following formula:
• Rl and R4 are separately selected from the group consisting of: hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein R2 is selected from H, a hydroxy, an alkoxy, a halo, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted cycloaliphatic group, an aryl,
• R5 is selected from the group consisting of H and ketone.
• R3 is selected from the group consisting of:
• R12, R13, R14 and R15 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid subgroup; a linear or branche
• Rl or R4 is selected from group consisting of:
• Rl or R4 is selected from the group consisting of: wherein Rl 6 is carbon or nitrogen; wherein Rl 7 is selected from the group consisting of hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8 is carbon or nitrogen; wherein R19 is selected from the group consisting of hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
• R4 or R wherein
• X is selected from the group consisting of , alkyl, substituted alkyl, sulfolamide, S0 2 alkyl, NHSO 2 , CH 2 , CH 2 CH 2 , SO 2 , CH 2 SO 2 , SO 2 CH 2 , OCH 2 CH 2 O, SO, CH 2 CH 2 SO, SOCH 2 CH 2 ; and wherein L, M and N are present or absent, and are selected from the group consisting of alkyl, NO 2 , halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, CF 3 , aniline, nitro, heterocycle, mono-substituted alkyl, di- substituted alkyl, and tri-substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, SOalkyl, NHSO 2 alkyl; wherein Y is selected from the group consisting of hydrogen, alkyl, substituted alky
• the present invention provides a pharmaceutical composition comprising a compound comprising the following formula:
• the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound comprising the following formula:
• R 1 is selected from the group consisting of H, CN and SO 2 -piperidine
• R 2 is selected from the group consisting of H, 4-Cl-Ph, Ph, and 2-Me-imidazole
• R 3 is selected from the group consisting of H, CH 2 -2-imidazole, and CH2-2-oxazole
• an apoptotic agent is selected from the present invention.
• the present invention provides a pharmaceutical composition comprising a compound comprising the following formula:
• R 1 is selected from the group consisting of H, 2,4-Cl 2 , 2-4-Me 2 , and 2,5-(CF 3 ) 2
• R 2 is selected from the group consisting of H, 4-Cl, 4-Me, 2,4-Cl 2 , 2,4-Me 2 , 3 -Cl
• X is selected from the group consisting of O and NH
• Y is selected from the group consisting of S, O, NCN, CO(3-CN-Ph), CO(4-CN-Ph), CO(4-Cl-Ph), and COEt; and an apoptotic agent.
• the present invention is not limited to particular apoptotic agents.
• the present invention provides, for example, the apoptotic agents described in U.S. Provisional Patent Nos. 60/607,599, and 60/641,040, and U.S. Patent Application Nos. 10/935,333, 10/886,450, 10/795,535, 10/634,114, 10/427,211, 10/427,212, 10/217,878, 09/767,283, 09/700,101, and related applications; each herein incorporated by reference in their entireties.
• Figure 2 shows plots of [Bz] versus V max (Figure 2A), [Bz] versus K m ( Figure 2B), and [Bz] versus V max /K m ( Figure 2C).
• benzodiazepine refers to a seven membered non-aromatic heterocyclic ring fused to a phenyl ring wherein the seven-membered ring has two nitrogen atoms, as part of the heterocyclic ring, hi some aspects, the two nitrogen atoms are in the 1 and 4 positions or the 1 and 5 positions, as shown in the general structures below:
• benzene refers to any chemical group containing 7 or more non-hydrogen atoms.
• substituted aliphatic refers to an alkane possessing less than 10 carbons where at least one of the aliphatic hydrogen atoms has been replaced by a halogen, an amino, a hydroxy, a nitro, a thio, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted cycloaliphatic, etc.). Examples of such include, but are not limited to, 1- chloroethyl and the like.
• substituted aryl refers to an aromatic ring or fused aromatic ring system consisting of no more than three fused rings at least one of which is aromatic, and where at least one of the hydrogen atoms on a ring carbon has been replaced by a halogen, an amino, a hydroxy, a nitro, a thio, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted cycloaliphatic). Examples of such include, but are not limited to, hydroxyphenyl and the like.
• cycloaliphatic refers to a cycloalkane possessing less than 8 carbons or a fused ring system consisting of no more than three fused cycloaliphatic rings. Examples of such include, but are not limited to, decalin and the like.
• substituted cycloaliphatic refers to a cycloalkane possessing less than 10 carbons or a fused ring system consisting of no more than three fused rings, and where at least one of the aliphatic hydrogen atoms has been replaced by a halogen, a nitro, a thio, an amino, a hydroxy, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted cycloaliphatic). Examples of such include, but are not limited to, 1- chlorodecalyl, bicyclo-heptanes, octanes, and nonanes ⁇ e.g., nonrbornyl) and the like.
• heterocyclic refers to a cycloalkane and/or an aryl ring system, possessing less than 8 carbons, or a fused ring system consisting of no more than three fused rings, where at least one of the ring carbon atoms is replaced by oxygen, nitrogen or sulfur. Examples of such include, but are not limited to, morpholino and the like.
• substituted heterocyclic refers to a cycloalkane and/or an aryl ring system, possessing less than 8 carbons, or a fused ring system consisting of no more than three fused rings, where at least one of the ring carbon atoms is replaced by oxygen, nitrogen or sulfur, and where at least one of the aliphatic hydrogen atoms has been replaced by a halogen, hydroxy, a thio, nitro, an amino, a ketone, an aldehyde, an ester, an amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted aryl, cycloaliphatic, or substituted cycloaliphatic). Examples of such include, but are not limited to 2-chloropyranyl.
• linker refers to a chain containing up to and including eight contiguous atoms connecting two different structural moieties where such atoms are, for example, carbon, nitrogen, oxygen, or sulfur.
• Ethylene glycol is one non-limiting example.
• lower-alkyl-substituted-amino refers to any alkyl unit containing up to and including eight carbon atoms where one of the aliphatic hydrogen atoms is replaced by an amino group. Examples of such include, but are not limited to, ethylamino and the like.
• lower-alkyl-substituted-halogen refers to any alkyl chain containing up to and including eight carbon atoms where one of the aliphatic hydrogen atoms is replaced by a halogen. Examples of such include, but are not limited to, chlorethyl and the like.
• acetylamino shall mean any primary or secondary amino that is acetylated. Examples of such include, but are not limited to, acetamide and the like.
• derivatives of a compound refers to a chemically modified compound wherein the chemical modification takes place either at a functional group of the compound or on the aromatic ring.
• epidermal hyperplasia refers to an abnormal multiplication or increase in the number of normal cells in normal arrangement in epidermal tissue. Epidermal hyperplasia is a characteristic of numerous disorders, including but not limited to, psoriasis.
• keratinocyte refers to a skin cell of the keratinized layer of the epidermis.
• fibroblast refers to mesodermally derived resident cells of connective tissue that secrete fibrillar procollagen, fibronectin and collegenase.
• pigment disorder refers to disorders involving skin pigment (e.g., melanin).
• pigment disorders include, but are not limited to, all forms of albinism, melasma, pigment loss after skin damage, and vitiligo.
• stent or “drug-eluting stent,” as used herein, refers to any device which when placed into contact with a site in the wall of a lumen to be treated, will also place fibrin at the lumen wall and retain it at the lumen wall. This can include especially devices delivered percutaneously to treat coronary artery occlusions and to seal dissections or aneurysms of splenic, carotid, iliac and popliteal vessels.
• the stent can also have underlying polymeric or metallic structural elements onto which the fibrin is applied or the stent can be a composite of fibrin intermixed with a polymer.
• a deformable metal wire stent such as that disclosed in U.S. Pat.
• No.: 4,886,062 herein incorporated by reference, could be coated with fibrin as set forth above in one or more coats (i.e., polymerization of fibrin on the metal framework by application of a fibrinogen solution and a solution of a fibrinogen-coagulating protein) or provided with an attached fibrin preform such as an encircling film of fibrin.
• the stent and fibrin could then be placed onto the balloon at a distal end of a balloon catheter and delivered by conventional percutaneous means (e.g. as in an angioplasty procedure) to the site of the restriction or closure to be treated where it would then be expanded into contact with the body lumen by inflating the balloon.
• the catheter can then be withdrawn, leaving the fibrin stent of the present invention in place at the treatment site.
• the stent may therefore provide both a supporting structure for the lumen at the site of treatment and also a structure supporting the secure placement of fibrin at the lumen wall.
• a drug-eluting stent allows for an active release of a particular drug at the stent, implementation site.
• the term "catheter” refers generally to a tube used for gaining access to a body cavity or blood vessel.
• valve or "vessel” refers to any lumen within a mammal. Examples include, but are not limited to, arteries, veins, capillaries, and biological lumen.
• restenosis refers to any valve which is narrowed. Examples include, but are not limited to, the reclosure of a peripheral or coronary artery following trauma to that artery caused by efforts to open a stenosed portion of the artery, such as, for example, by balloon dilation, ablation, atherectomy or laser treatment of the artery.
• angioplasty or “balloon therapy” or “balloon angioplasty” or “percutaneous transluminal coronary angioplasty” refers to a method of treating blood vessel disorders that involves the use of a balloon catheter to enlarge the blood vessel and thereby improve blood flow.
• cardiac catheterization or “coronary angiogram” refers to a test used to diagnose coronary artery disease using a catheterization procedure. Such a procedure may involve, for example, the injection of a contrast dye into the coronary arteries via a catheter, permitting the visualization of a narrowed or blocked artery.
• subject refers to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably includes humans.
• the term "subject” generally refers to an individual who will receive or who has received treatment (e.g., administration of a compound of the present invention and optionally one or more other agents) for a condition characterized by the dysregulation of apoptotic processes.
• diagnosis refers to the to recognition of a disease by its signs and symptoms (e.g., resistance to conventional therapies), or genetic analysis, pathological analysis, histological analysis, and the like.
• anticancer agent or “conventional anticancer agent” refer to any chemotherapeutic compounds, radiation therapies, or surgical interventions, used in the treatment of cancer.
• in vitro refers to an artificial environment and to processes or reactions that occur within an artificial environment.
• in vitro environments include, but are not limited to, test tubes and cell cultures.
• in vivo refers to the natural environment (e.g., an animal or a cell) and to processes or reaction that occur within a natural environment.
• the term "host cell” refers to any eukaryotic or prokaryotic cell (e.g., mammalian cells, avian cells, amphibian cells, plant cells, fish cells, and insect cells), whether located in vitro or in vivo.
• eukaryotic or prokaryotic cell e.g., mammalian cells, avian cells, amphibian cells, plant cells, fish cells, and insect cells
• cell culture refers to any in vitro culture of cells. Included within this term are continuous cell lines (e.g., with an immortal phenotype), primary cell cultures, finite cell lines (e.g., non-transformed cells), and any other cell population maintained in vitro, including oocytes and embryos.
• the "target cells" of the compositions and methods of the present invention include, refer to, but are not limited to, lymphoid cells or cancer cells.
• Lymphoid cells include B cells, T cells, and granulocytes.
• Granulocyctes include eosinophils and macrophages.
• target cells are continuously cultured cells or uncultered cells obtained from patient biopsies.
• Cancer cells include tumor cells, neoplastic cells, malignant cells, metastatic cells, and hyperplastic cells.
• Neoplastic cells can be benign or malignant. Neoplastic cells are benign if they do not invade or metastasize. A malignant cell is one that is able to invade and/or metastasize.
• Hyperplasia is a pathologic accumulation of cells in a tissue or organ, without significant alteration in structure or function. hi one specific embodiment, the target cells exhibit pathological growth or proliferation.
• the term "pathologically proliferating or growing cells” refers to a localized population of proliferating cells in an animal that is not governed by the usual limitations of normal growth.
• the term "un-activated target cell” refers to a cell that is either in the G 0 phase or one in which a stimulus has not been applied.
• the term “activated target lymphoid cell” refers to a lymphoid cell that has been primed with an appropriate stimulus to cause a signal transduction cascade, or alternatively, a lymphoid cell that is not in G 0 phase.
• Activated lymphoid cells may proliferate, undergo activation induced cell death, or produce one or more of cytotoxins, cytokines, and other related membrane-associated proteins characteristic of the cell type (e.g., CDS + or CD4 + ). They are also capable of recognizing and binding any target cell that displays a particular antigen on its surface, and subsequently releasing its effector molecules.
• activated cancer cell refers to a cancer cell that has been primed with an appropriate stimulus to cause a signal transduction.
• An activated cancer cell may or may not be in the Go phase.
• An activating agent is a stimulus that upon interaction with a target cell results in a signal transduction cascade.
• activating stimuli include, but are not limited to, small molecules, radiant energy, and molecules that bind to cell activation cell surface receptors.
• Responses induced by activation stimuli can be characterized by changes in, among others, intracellular Ca 2+ , superoxide, or hydroxyl radical levels; the activity of enzymes like kinases or phosphatases; or the energy state of the cell.
• activating agents also include transforming oncogenes. hi one aspect, the activating agent is any agent that binds to a cell surface activation receptor.
• T cell receptor ligand a B cell activating factor
• TNF a TNF
• Fas ligand Fas ligand
• CD40 ligand a proliferation inducing ligand
• APRIL proliferation inducing ligand
• cytokine a chemokine
• hormone an amino acid (e.g., glutamate), a steroid, a B cell receptor ligand, gamma irradiation, UV irradiation, an agent or condition that enhances cell stress, or an antibody that specifically recognizes and binds a cell surface activation receptor (e.g., anti-CD4, anti-CD8, anti-CD20, anti-TACI, anti-BCMA, anti- TNF receptor, anti-CD40, anti-CD3, anti-CD28, anti-B220, anti-CD38, and-CD19, and anti- CD21).
• BAFF B cell activating factor
• TNF TNF
• Fas ligand Fas ligand
• CD40 ligand
• BCMA is B cell maturation antigen receptor and TACI is transmembrane activator and CAML interactor. (Gross, A. et al. (2000); Laabi, Y. et al. (1992) and Madry, C. et al. (1998)).
• Antibodies include monoclonal or polyclonal or a mixture thereof.
• T cell ligand examples include, but are not limited to, a peptide that binds to an MHC molecule, a peptide MHC complex, or an antibody that recognizes components of the T cell receptor.
• B cell ligand examples include, but are not limited to, a molecule or antibody that binds to or recognizes components of the B cell receptor.
• reagents that bind to a cell surface activation receptor include, but are not limited to, the natural ligands of these receptors or antibodies raised against them (e.g., anti- CD20).
• RITUXIN Genentech, Inc., San Francisco, CA is a commercially available anti-CD 20 chimeric monoclonal antibody.
• agents or conditions that enhance cell stress include heat, radiation, oxidative stress, or growth factor withdrawal and the like.
• growth factors include, but are not limited to serum, IL-2, platelet derived growth factor ("PDGF”), and the like.
• effective amount refers to the amount of a compound (e.g., a compound of the present invention) sufficient to effect beneficial or desired results.
• An effective amount can be administered in one or more administrations, applications or dosages and is not limited intended to be limited to a particular formulation or administration route.
• the term "dysregulation of the process of cell death” refers to any aberration in the ability of (e.g. , predisposition) a cell to undergo cell death via either necrosis or apoptosis.
• Dysregulation of cell death is associated with or induced by a variety of conditions, including for example, autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, graft-versus-host disease, myasthenia gravis, Sjogren's syndrome, etc.), chronic inflammatory conditions (e.g., psoriasis, asthma and Crohn's disease), hyperproliferative disorders (e.g., tumors, B cell lymphomas, T cell lymphomas, etc.), viral infections (e.g., herpes, papilloma, HIV), and other conditions such as osteoarthritis and atherosclerosis.
• autoimmune disorders e.g., systemic lupus erythemat
• the dysregulation when the dysregulation is induced by or associated with a viral infection, the viral infection may or may not be detectable at the time dysregulation occurs or is observed. That is, viral-induced dysregulation can occur even after the disappearance of symptoms of viral infection.
• a "hyperproliferative disorder,” as used herein refers to any condition in which a localized population of proliferating cells in an animal is not governed by the usual limitations of normal growth. Examples of hyperproliferative disorders include tumors, neoplasms, lymphomas and the like. A neoplasm is said to be benign if it does not undergo, invasion or metastasis and malignant if it does either of these. A metastatic cell or tissue means that the cell can invade and destroy neighboring body structures.
• Hyperplasia is a form of cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function.
• Metaplasia is a form of controlled cell growth in which one type of fully differentiated cell substitutes for another type of differentiated cell. Metaplasia can occur in epithelial or connective tissue cells. A typical metaplasia involves a somewhat disorderly metaplastic epithelium.
• autoimmune disorder refers to any condition in which an organism produces antibodies or immune cells which recognize the organism's own molecules, cells or tissues.
• Non-limiting examples of autoimmune disorders include autoimmune hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, Celiac Sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjorgren syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, vitiligo, tuberculosis, and the like.
• chronic inflammatory condition refers to a condition wherein the organism's immune cells are activated. Such a condition is characterized by a persistent inflammatory response with pathologic sequelae. This state is characterized by infiltration of mononuclear cells, proliferation of fibroblasts and small blood vessels, increased connective tissue, and tissue destruction.
• chronic inflammatory diseases include, but are not limited to, Crohn's disease, psoriasis, chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, and asthma.
• Autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus can also result in a chronic inflammatory state.
• co-administration refers to the administration of at least two agent(s) (e.g., a compound of the present invention) or therapies to a subject.
• the co-administration of two or more agents/therapies is concurrent, hi other embodiments, a first agent/therapy is administered prior to a second agent/therapy.
• the appropriate dosage for co-administration can be readily determined by one skilled in the art.
• the respective agents/therapies are administered at lower dosages than appropriate for their administration alone.
• co-administration is especially desirable in embodiments where the co-administration of the agents/therapies lowers the requisite dosage of a known potentially harmful (e.g., toxic) agent(s).
• a known potentially harmful agent(s) e.g., toxic
• the term "toxic” refers to any detrimental or harmful effects on a cell or tissue as compared to the same cell or tissue prior to the administration of the toxicant.
• the term "pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo, in vivo or ex vivo.
• pharmaceutically acceptable carrier refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
• the compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants. (See e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975]).
• the term "pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof.
• salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
• acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
• Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
• bases include, but are not limited to, alkali metals (e.g., sodium) hydroxides, alkaline earth metals (e.g., magnesium), hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is C 1-4 alkyl, and the like.
• salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate,
• salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
• salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
• solid phase supports or “solid supports,” are used in their broadest sense to refer to a number of supports that are available and known to those of ordinary skill in the art.
• Solid phase supports include, but are not limited to, silica gels, resins, derivatized plastic films, glass beads, cotton, plastic beads, alumina gels, and the like.
• solid supports also include synthetic antigen-presenting matrices, cells, liposomes, and the like. A suitable solid phase support may be selected on the basis of desired end use and suitability for various protocols.
• solid phase supports may refer to resins such as polystyrene (e.g., PAM-resin obtained from Bachem, Inc., Peninsula Laboratories, etc.), POLYHIPE) resin (obtained from Aminotech, Canada), polyamide resin (obtained from Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (TENTAGEL, Rapp Polymere, Tubingen, Germany) or polydimethylacrylamide resin (obtained from Milligen/Biosearch, California).
• polystyrene e.g., PAM-resin obtained from Bachem, Inc., Peninsula Laboratories, etc.
• POLYHIPE polyamide resin
• TENTAGEL Rapp Polymere, Tubingen, Germany
• polydimethylacrylamide resin obtained from Milligen/Biosearch, California
• pathogen refers a biological agent that causes a disease state (e.g., infection, cancer, etc.) in a host.
• Pathogens include, but are not limited to, viruses, bacteria, archaea, fungi, protozoans, mycoplasma, prions, and parasitic organisms.
• bacteria and bacterium refer to all prokaryotic organisms, including those within all of the phyla in the Kingdom Procaryotae. It is intended that the term encompass all microorganisms considered to be bacteria including Mycoplasma, Chlamydia, Actinomyces, Streptomyces, and Rickettsia. All forms of bacteria are included within this definition including cocci, bacilli, spirochetes, spheroplasts, protoplasts, etc.
• prokaryotic organisms which are gram negative or gram positive.
• Gram negative and gram positive refer to staining patterns with the Gram-staining process which is well known in the art. (See e.g., Finegold and Martin, Diagnostic Microbiology, 6th Ed., CV Mosby St. Louis, pp. 13-15 [1982]).
• Gram positive bacteria are bacteria which retain the primary dye used in the Gram stain, causing the stained cells to appear dark blue to purple under the microscope.
• Gram negative bacteria do not retain the primary dye used in the Gram stain, but are stained by the counterstain. Thus, gram negative bacteria appear red.
• microorganism refers to any species or type of microorganism, including but not limited to, bacteria, archaea, fungi, protozoans, mycoplasma, and parasitic organisms.
• the present invention contemplates that a number of microorganisms encompassed therein will also be pathogenic to a subject.
• fungi is used in reference to eukaryotic organisms such as the molds and yeasts, including dimorphic fungi.
• virus refers to minute infectious agents, which with certain exceptions, are not observable by light microscopy, lack independent metabolism, and are able to replicate only within a living host cell.
• the individual particles i.e., virions
• the individual particles typically consist of nucleic acid and a protein shell or coat; some virions also have a lipid containing membrane.
• the term “virus” encompasses all types of viruses, including animal, plant, phage, and other viruses.
• sample as used herein is used in its broadest sense.
• a sample suspected of indicating a condition characterized by the dysregulation of apoptotic function may comprise a cell, tissue, or fluids, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern blot analysis), RNA (in solution or bound to a solid support such as for Northern blot analysis), cDNA (in solution or bound to a solid support) and the like.
• a 5 sample suspected of containing a protein may comprise a cell, a portion of a tissue, an extract containing one or more proteins and the like.
• the terms “purified” or “to purify” refer, to the removal of undesired components from a sample.
• substantially purified refers to molecules that are at least 60% free, preferably 75% free, and most preferably 90%, or
• antigen binding protein refers to proteins which bind to a specific antigen.
• Antigen binding proteins include, but are not limited to, immunoglobulins, including polyclonal, monoclonal, chimeric, single chain, and humanized antibodies, Fab fragments, F(ab')2 fragments, and Fab expression libraries.
• polyclonal antibodies 15 procedures known in the art are used for the production of polyclonal antibodies.
• various host animals can be immunized by injection with the peptide corresponding to the desired epitope including but not limited to rabbits, mice, rats, sheep, goats, etc.
• the peptide is conjugated to an immunogenic carrier (e.g., diphtheria toxoid, bovine serum albumin (BSA), or keyhole limpet hemocyanin
• an immunogenic carrier e.g., diphtheria toxoid, bovine serum albumin (BSA), or keyhole limpet hemocyanin
• adjuvants are used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (Bacille Calmette-Guerin) and
• any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used (See e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). These include, but are not limited to, the hybridoma technique
• Antibody fragments that contain the idiotype (antigen binding region) of the antibody molecule can be generated by known techniques.
• fragments include but are not limited to: the F(ab')2 fragment that can be produced by pepsin digestion of an antibody molecule; the Fab' fragments that can be generated by reducing the disulfide bridges of an F(ab')2 fragment, and the Fab fragments that can be generated by treating an antibody molecule with papain and a reducing agent.
• Genes encoding antigen binding proteins can be isolated by methods known in the art.
• screening for the desired antibody can be accomplished by techniques known in the art ⁇ e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich” immunoassays, imrnunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), Western Blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays, etc.), complement fixation assays, immunofluorescence assays, protein A assays, and imniunoelectrophoresis assays, etc.) etc.
• radioimmunoassay e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich” immunoassays, imrnun
• immunoglobulin refers to proteins that bind a specific antigen.
• Immunoglobulins include, but are not limited to, polyclonal, monoclonal, chimeric, and humanized antibodies, Fab fragments, F(ab') 2 fragments, and includes immunoglobulins of the following classes: IgG, IgA, IgM, IgD, IbE, and secreted immunoglobulins (slg).
• Immunoglobulins generally comprise two identical heavy chains and two light chains.
• the terms “antibody” and “immunoglobulin” also encompass single chain antibodies and two chain antibodies.
• epitope refers to that portion of an antigen that makes contact with a particular immunoglobulin.
• epitope refers to that portion of an antigen that makes contact with a particular immunoglobulin.
• an antigenic determinant may compete with the intact antigen (i.e., the "immunogen” used to elicit the immune response) for binding to an antibody.
• telomere binding when used in reference to the interaction of an antibody and a protein or peptide means that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A,” the presence of a protein containing epitope A (or free, unlabelled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.
• non-specific binding and “background binding” when used in reference to the interaction of an antibody and a protein or peptide refer to an interaction that is not dependent on the presence of a particular structure (i.e., the antibody is binding to proteins in general rather that a particular structure such as an epitope).
• the term “modulate” refers to the activity of a compound (e.g., a compound of the present invention) to affect (e.g., to promote or retard) an aspect of cellular function, including, but not limited to, cell growth, proliferation, apoptosis, and the like.
• the term "competes for binding” is used in reference to a first molecule (e.g., a first compound of the present invention) with an activity that binds to the same substrate (e.g., the oligomycin sensitivity conferring protein in mitochondrial ATP synthase) as does a second molecule (e.g., a second compound of the present invention or other molecule that binds to the oligomycin sensitivity conferring protein in mitochondrial ATP synthase, etc.).
• the efficiency e.g., kinetics or thermodynamics
• binding by the first molecule may be the same as, or greater than, or less than, the efficiency of the substrate binding to the second molecule.
• the equilibrium binding constant (K D ) for binding to the substrate may be different for the two molecules.
• the term "instructions for administering said compound to a subject,” and grammatical equivalents thereof, includes instructions for using the compositions contained in a kit for the treatment of conditions characterized by the dysregulation of apoptotic processes in a cell or tissue (e.g., providing dosing, route of administration, decision trees for treating physicians for correlating patient-specific characteristics with therapeutic courses of action).
• the term also specifically refers to instructions for using the compositions contained in the kit to treat autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, graft- versus-host disease, myasthenia gravis, Sjogren's syndrome, etc.), chronic inflammatory conditions (e.g., psoriasis, asthma and Crohn's disease), hyperproliferative disorders (e.g., tumors, B cell lymphomas, T cell lymphomas, etc.), viral infections (e.g., herpes virus, papilloma virus, HIV), and other conditions such as osteoarthritis and atherosclerosis, and the like.
• autoimmune disorders e.g., systemic lupus erythematosus, rheumatoid arthritis, graft- versus-host disease, myasthenia gravis, Sjogren's syndrome, etc.
• chronic inflammatory conditions e.g., p
• test compound refers to any chemical entity, pharmaceutical, drug, and the like, that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function, or otherwise alter the physiological or cellular status of a sample (e.g., the level of dysregulation of apoptosis in a cell or tissue).
• Test compounds comprise both known and potential therapeutic compounds.
• a test compound can be determined to be therapeutic by using the screening methods of the present invention.
• a "known therapeutic compound” refers to a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention.
• test compounds are agents that modulate apoptosis in cells:
• third party refers to any entity engaged in selling, warehousing, distributing, or offering for sale a test compound contemplated for administered with a compound for treating conditions characterized by the dysregulation of apoptotic processes.
• benzodiazepine compounds have been widely studied and reported to be effective medicaments for treating a number of disease.
• U.S. 4,076823, 4,110,337, 4,495,101, 4,751,223 and 5,776,946, each incorporated herein by reference in its entirety report that certain benzodiazepine compounds are effective as analgesic and anti-inflammatory agents.
• U.S. 5,324,726 and U.S. 5,597,915, each incorporated by reference in its entirety report that certain benzodiazepine compounds are antagonists of cholecystokinin and gastrin and thus might be useful to treat certain gastrointestinal disorders.
• benzodiazepine compounds have been studied as inhibitors of human neutrophil elastase in the treating of human neutrophil elastase-mediated conditions such as myocardial ischemia, septic shock syndrome, among others (See e.g., U.S. 5,861,380 incorporated herein by reference in its entirety).
• Benzodiazepine compounds are known to bind to benzodiazepine receptors in the central nervous system (CNS) and thus have been used to treat various CNS disorders including anxiety and epilepsy. Peripheral benzodiazepine receptors have also been identified, which receptors may incidentally also be present in the CNS.
• the present invention demonstrates that benzodiazepines and related compounds have pro-apoptotic and cytotoxic properties useful in the treatment of transformed cells grown in tissue culture. The route of action of these compounds is not through the previously identified benzodiazepine receptors.
• the present invention provides compounds that interact, directly or indirectly, with particular mitochondrial proteins to elicit the desired biological effects.
• the present invention provides a number of novel compounds and previously known compounds directed against novel cellular targets to achieve desired biological results.
• the present invention provides methods for using such compounds to regulate biological processes.
• the present invention also provides drug-screening methods to identify and optimize compounds.
• the present invention further provides diagnostic markers for identifying diseases and conditions, for monitoring treatment regimens, and/or for identifying optimal therapeutic courses of action.
• the present invention provides novel chemical compounds, methods for their discovery, and their therapeutic, research, and diagnostic use.
• the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproriferation, and the like.
• compositions and methods of the present invention are described in more detail in the following sections: I. Modulators of Cell Death; II. Modulators of Cell Growth and Proliferation; III. Exemplary Compounds; IV. Pharmaceutical compositions, formulations, and exemplary administration routes and dosing considerations; V. Drug screens; VI. Therapeutic Applications; and VII. ATPase Inhibitors And Methods For Identifying Therapeutic Inhibitors.
• the present invention regulates apoptosis through the exposure of cells to compounds.
• the effect of compounds can be measured by detecting any number of cellular changes.
• Cell death may be assayed as described herein and in the art.
• cell lines are maintained under appropriate cell culturing conditions (e.g., gas (CO 2 ), temperature and media) for an appropriate period of time to attain exponential proliferation without density dependent constraints.
• Cell number and or viability are measured using standard techniques, such as trypan blue exclusion/hemo-cytometry, or MTT dye conversion assay.
• the cell may be analyzed for the expression of genes or gene products associated with aberrations in apoptosis or necrosis.
• exposing the present invention to a cell induces apoptosis.
• the present invention causes an initial increase in cellular ROS levels (e.g., O 2 " ).
• exposure of the compounds of the present invention to a cell causes an increase in cellular O 2 ' levels
• the increase in cellular O 2 " levels resulting from the compounds of the present invention is detectable with a redox-sensitive agent that reacts specifically with O 2 " (e.g., dihyroethedium (DHE)).
• DHE dihyroethedium
• increased cellular O 2 " levels resulting from compounds of the present invention diminish after a period of time (e.g., 10 minutes). In other embodiments, it is contemplated that increased cellular O 2 " levels resulting from the compounds of the present invention diminish after a period of time and increase again at a later time (e.g., 10 hours), hi further embodiments, it is contemplated that increased cellular O 2 " levels resulting from the compounds of the present invention diminish at 1 hour and increase again after 4 hours.
• an early increase in cellular O 2 " levels, followed by a diminishing in cellular O 2 " levels, followed by another increase in cellular O 2 " levels resulting from the compounds of the present invention is due to different cellular processes (e.g., bimodal cellular mechanisms).
• the present invention causes a collapse of a cell's mitochondrial ⁇ m .
• a collapse of a cell's mitochondrial ⁇ m resulting from the present invention is detectable with a mitochondria-selective potentiometric probe (e.g., DiOC 6 ).
• a collapse of a cell's mitochondrial ⁇ m resulting from the present invention occurs after an initial increase in cellular O 2 " levels.
• the present invention enables caspace activation. In other embodiments, it is contemplated that the present invention causes the release of cytochrome c from mitochondria. In further embodiments, it is contemplated that the present invention alters cystolic cytochrome c levels. In still other embodiments, it is contemplated that altered cystolic cytochrome c levels resulting from the present invention are detectable with immunoblotting cytosolic fractions. In preferred embodiments, it is contemplated that diminished cystolic cytochrome c levels resulting from the present invention are detectable after a period of time ⁇ e.g., 10 hours). In further preferred embodiments, it is contemplated that diminished cystolic cytochrome c levels resulting from the present invention are detectable after 5 hours.
• the present invention causes the opening of the mitochondrial PT pore.
• the cellular release of cytochrome c resulting from the present invention is consistent with a collapse of mitochondrial ⁇ m .
• the present invention causes an increase in cellular O 2 " levels after a mitochondrial ⁇ m collapse and a release of cytochrome c.
• a rise in cellular O 2 " levels is caused by a mitochondrial ⁇ m collapse and release of cytochrome c resulting from the present invention.
• the present invention causes cellular caspase activation
• caspase activation resulting from the present invention is measurable with a pan-caspase sensitive fluorescent substrate (e.g., FAM-VAD-fmk).
• caspase activation resulting from the present invention tracks with a collapse of mitochondrial ⁇ m .
• the present invention causes an appearance of hypodiploid DNA. Ih preferred embodiments, it is contemplated that an appearance of hypodiploid DNA resulting from the present invention is slightly delayed with respect to caspase activation.
• the molecular target for the present invention is found within mitochondria, hi further embodiments, it is contemplated that the molecular target of the present invention involves the mitochondrial ATPase.
• the primary sources of cellular ROS include redox enzymes and the mitochondrial respiratory chain (hereinafter MRC).
• MRC mitochondrial respiratory chain
• cytochrome c oxidase (complex IV of the MRC) inhibitors e.g., NaN 3 ) preclude a present invention dependent increase in cellular ROS levels.
• the ubiquinol-cytochrome c reductase component of MRC complex III inhibitors preclude a present invention dependent increase in ROS levels.
• an increase in cellular ROS levels result from the binding of the compounds of the present invention to a target within mitochondria.
• the compounds of the present invention oxidize 2',7'-dichlorodihydrofluorescm (hereinafter DCF) diacetate to DCF.
• DCF is a redox-active species capable of generating ROS.
• DCF is a redox-active species capable of generating ROS.
• the rate of DCF production resulting from the present invention increases after a lag period.
• Antimycin A generates O 2 " by inhibiting ubiquinol-cytochrome c reductase.
• the present invention increases the rate of ROS production in an equivalent manner to antimycin A.
• the present invention increases the rate of ROS production in an equivalent manner to antimycin A under aerobic conditions supporting state 3 respiration.
• the compounds of the present invention do not directly target the MPT pore.
• the compounds of the present invention do not generate substantial ROS in the subcellular S 15 fraction ⁇ e.g., cytosol; microsomes).
• the compounds of the present invention do not stimulate ROS if mitochondria are in state 4 respiration.
• MRC complexes I — III are the primary sources of ROS within mitochondria.
• the primary source of an increase in cellular ROS levels resulting from the dependent invention emanates from these complexes as a result of inhibiting the mitochondrial F 1 F 0 -ATPaSe.
• the present invention inhibits mitochondrial ATPase activity of bovine sub-mitochondrial particles (hereinafter SMPs).
• SMPs bovine sub-mitochondrial particles
• the compounds of the present invention bind to the OSCP component of the mitochondrial F 1 F 0 -ATPaSe.
• Oligomycin is a macrolide natural product that binds to the mitochondrial F 1 F 0 - ATPase, induces a state 3 to 4 transition, and as a result, generates ROS (e.g., O 2 " ).
• the compounds of the present invention bind the OSCP component of the mitochondrial F 1 F 0 -ATPaSe.
• the compounds of the present invention bind the junction between the OSCP and the F 1 subunit of the mitochondrial F 1 F 0 -ATPaSe.
• the compounds of the present invention bind the F 1 subunit.
• screening assays of the present invention permit detection of binding partners of the OSCP, F 1 , or OSCP/ F 1 junction.
• OSCP is an intrinsically fluorescent protein, hi certain embodiments, titrating a solution of test compounds of the present invention into an E. CoIi sample overexpressed with OSCP results in quenching of the intrinsic OSCP fluorescence, hi other embodiments, fluorescent or radioactive test compounds can be used in direct binding assays, hi other embodiments, competition binding experiments can be conducted, hi this type of assay, test compounds are assessed for their ability to compete with Bz-423 for binding to, for example, the OSCP. In some embodiments, the compounds of the present invention cause a reduced increase in cellular ROS levels and reduced apoptosis in cells through regulation of the OSCP gene
• the present invention functions by altering the molecular motions of the ATPase motor.
• Rl comprises a chemical moiety comprising a hydrogen bonding proton donor (e.g., a hydroxy! group, a phenol group, an amide group, a sulfonamide group, an amine group, an aniline group, a benzimidizalone group, a carbamate group, and an imidizole group); and R2 comprises a hydrophobic chemical moiety.
• Rl is selected from the group consisting of:
• Rl ', R2, R3 and R4 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons and at least one hydroxy subgroup; a linear or branched, saturated or unsaturated, substituted or non- substituted, aliphatic chain having at least 2 carbons and having at least one thiol subgroup; a linear or branched, saturated or unsaturated, substituted or non-substituted, aliphatic chain having at least 2 carbons wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated, substituted or non-substituted, aliphatic chain having at least
• R2 is selected from group consisting of: napthalalanine
• Rl is selected from the group consisting of:
• the composition comprises the following formula: wherein R3 is selected from the group consisting of Hydrogen; amino; and a linear or branched, saturated or unsaturated, substituted (e.g., substituted with amines, esters, amides or phosphatases) or non-substituted, aliphatic chain having at least 2 carbons; R4 is selected from the group consisting of H, a ketone, and a nitrogen; and
• R5 is selected from H, a hydroxy, an alkoxy, a carboxylic acid, a carboxylic ester, a halogen, a nitro, a sulfonamide, an amide, a carbamate, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NO 2 ; SR'; and NR' 2 , wherein R' is defined as a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxyl subgroup; a
• R2 is any chemical group that permits the compound to bind to OSCP.
• R2 comprises a hydrophobic aromatic group
• R2 comprises a hydrophobic aromatic group larger than benzene (e.g., a benzene ring with non-hydrogen substituents, a moiety having two or more aromatic rings, a moiety with 7 or more carbon atoms, etc.).
• aliphatic represents the groups commonly known as alkyl, alkenyl, alkynyl, alicyclic.
• aryl as used herein represents a single aromatic ring such as a phenyl ring, or two or more aromatic rings that are connected to each other (e.g., bisphenyl) or fused together (e.g., naphthalene or anthracene).
• the aryl group can be optionally substituted with a lower aliphatic group (e.g., C 1 -C 4 alkyl, alkenyl, alkynyl, or C 3 -C 6 alicyclic).
• the aliphatic and aryl groups can be further substituted by one or more functional groups such as -NH 2 , -NHCOCH 3 , -OH, lower alkoxy (C 1 -C 4 ), halo (-F, - Cl, -Br, or -I). It is preferable that R 1 is primarily a nonpolar moiety.
• a moiety that participates in hydrogen bonding represents a group that can accept or donate a proton to form a hydrogen bond thereby.
• moieties that participate in hydrogen bonding include a fluoro, oxygen-containing and nitrogen-containing groups that are well- known in the art.
• oxygen-containing groups that participate in hydrogen bonding include: hydroxy, lower alkoxy, lower carbonyl, lower carboxyl, lower ethers and phenolic groups.
• the qualifier "lower” as used herein refers to lower aliphatic groups (C 1 - C 4 ) to which the respective oxygen-containing functional group is attached.
• the term “lower carbonyl” refers to inter alia, formaldehyde, acetaldehyde.
• the hydrogen-bond acceptor in the present invention can be the ⁇ electrons of an aromatic ring.
• the hydrogen bond participants of this invention do not include those groups containing metal atoms such as boron.
• the hydrogen bonds formed within the scope of practicing this invention do not include those formed between two hydrogens, known as "dihydrogen bonds.” ⁇ See, R.H. Crabtree, Science, 282:2000-2001 [1998], for further description of such dihydrogen bonds).
• the term "heterocyclic” represents, for example, a 3-6 membered aromatic or nonaromatic ring containing one or more heteroatoms.
• the heteroatoms can be the same or different from each other.
• at least one of the heteroatom's is nitrogen.
• Other heteroatoms that can be present on the heterocyclic ring include oxygen and sulfur.
• Aromatic and nonaromatic heterocyclic rings are well-known in the art. Some nonlimiting examples of aromatic heterocyclic rings include pyridine, pyrimidine, indole, purine, quinoline and isoquinoline. Nonlimiting examples of nonaromatic heterocyclic compounds include piperidine, piperazine, morpholine, pyrrolidine and pyrazolidine. Examples of oxygen containing heterocyclic rings include, but not limited to furan, oxirane, 2H-pyran, 4H-pyran, 2H-chromene, and benzofuran. Examples of sulfur-containing heterocyclic rings include, but are not limited to, thiophene, benzothiophene, and parathiazine.
• nitrogen containing rings include, but not limited to, pyrrole, pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazoline, imidazolidine, pyridine, piperidine, pyrazine, piperazine, pyrimidine, indole, purine, benzimidazole, quinoline, isoquinoline, triazole, and triazine.
• heterocyclic rings containing two different heteroatoms include, but are not limited to, phenothiazine, morpholine, parathiazine, oxazine, oxazole, thiazine, and thiazole.
• WW, XX, YY and ZZ are present or absent, and are selected from the group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri- substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, NHSO 2 alkyl; and wherein Z is selected from the group consisting of
• R5 is selected from the group consisting of alkyl, mono-substituted alkyl, di-substituted alkyl, and tri- substituted alkyl.
• Additional exemplary compounds of the present invention include, but are not limited to,
• Rl is selected from the group consisting of:
• alkyl, and substituted alkly O 2 Ar.
• Z and Y are separately selected from the group consisting of O, N
• the present invention provides a composition comprising the following formula:
• R2 is selected from the group consisting of
• R3 is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, carboxylic acid, amide, SO 2 NH 2 , NHSO 2 alkyl, and NO 2 ; wherein BB, CC, DD, and R4 are present or absent, and are selected from the group consisting of hydrogen, CF 3 , NO 2 , alkyl, halogen, OH, O-alkyl, nitro, OCH 2 CH 2 OH, SO 2 H, mono-substituted alkyl, di-substituted alkyl, tri-substituted alkyl, CO 2 H, heterocycle, SO 2 NH 2 , SO 2 NH-alkyl, NHSO 2 alkyl, methyl ester, propyl ester, and ethyl ester; and wherein R5 is selected from the group consisting OfNHSO 2 , CH 2 NHSO 2 , CH 2 CH 2 NHSO 2 , CH 2 CH 2 CH 2 NHSO 2 , SOSO
• R1 H, alkyl, or substituted alkyl
• R2 H, alkyl, or substituted alkyl
• sterochemistry is R, S, or racemic
• a halo having aliphatic of an aryl
• a halo having aliphatic of an aryl
• halo an having aliphatic of an aryl, and a heterocyclic
• halo an having aliphatic of an aryl, and a heterocyclic
• R1 H, alkyl, or substituted alkyl
• R4 H, alkyl, or substituted alkyl
• sterochemistry is R, S, or racemic
• R2 is selected from hydrogen, a hydroxy, an alkoxy, a halo, an amino, a lower-alkyl-a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of ⁇ 10 carbons, a substituted cycloaliphatic group, an aryl, and a heterocyclic
• R 1 is selected from napthalalanine; phenol; 1-Napthalenol; 2-Napthalenol;
• composition comprising the following formula:
• Ri is selected from:
• the stereochemistry of all derivatives embodied in the present invention is R, S, or racemic.
• the present invention provides a composition comprising the following formula:
• Rl is a nitrogen atom or a carbon atom
• R2 is carbon or nitrogen
• R3 comprises a chemical moiety comprising a heterocyclic group containing 3 or more carbon atoms
• R4 and R5 are separately selected from the group consisting of: hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety
• R6 is selected from H, a hydroxy, an alkoxy, a halogen, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20
• R12, R13, R14 and R15 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid subgroup; a linear or branche
• R4 or R5 are selected from group consisting of:
• R.4 or R5 is selected from the group consisting of:
• Rl 6 is carbon or nitrogen; wherein Rl 7 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8 is carbon or nitrogen; wherein Rl 9 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
• R4 or R5 is , wherein
• X is selected from the group consisting of alkyl, substituted alkyl, sulfolamide, S0 2 alkyl, NHSO 2 , CH 2 , CH 2 CH 2 , SO 2 , CH 2 SO 2 , SO 2 CH 2 , OCH 2 CH 2 O, SO, CH 2 CH 2 SO, SOCH 2 CH 2 ; and wherein L, M and N are present or absent, and are selected from the group consisting of alkyl, NO 2 , halogen, OH, O- Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, CF 3 , aniline, nitro, heterocycle, mono-substituted alkyl, di- substituted alkyl, and tri-substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, SOalkyl, NHSO 2 alkyl; wherein Y is selected from the group consisting of hydrogen, alkyl, substituted alkyl,
• the composition is:
• the present invention provides a composition comprising the following formula:
• Rl is a nitrogen atom or a carbon atom
• R2 is selected from H, a hydroxy, an alkoxy, a halo, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NO 2 ; SR'; and NR' 2 , wherein R' is defined as a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxyl subgroup; a linear or
• R12, Rl 3, R14 and Rl 5 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid subgroup; a linear or
• R4 or R5 is selected from the group consisting of:
• Rl 6 is carbon or nitrogen; wherein Rl 7 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8 is carbon or nitrogen; wherein Rl 9 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
• R4 or R wherein
• X is selected from the group consisting of
• the present invention provides a composition comprising the following formula:
• Rl is carbon or nitrogen;
• R2 is selected from H, a hydroxy, an alkoxy, a halogen, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic group consisting of less than 10 carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NO 2 ; SR'; and NR' 2 , wherein R' is defined as a linear or branched, saturated or unsaturated aliphatic chain having at least one carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxyl subgroup; a linear or branched, saturated or unsatur
• R3 is selected from the group consisting of:
• R12, R13, R14 and R15 are selected from the group consisting of: hydrogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 1 carbon; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one hydroxy subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons, and having at least one ketone subgroup; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid subgroup; a linear or branche
• R4 or R5 are selected from group consisting of:
• n 0-5;
• R4 or R5 is selected from the group consisting of: an( i
• Rl 6 is carbon or nitrogen; wherein Rl 7 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8 is carbon or nitrogen; wherein R19 is selected from the group consisting of hydrogen; halogen; CH 3 ; a linear or branched, saturated or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical moiety; and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
• R4 or R wherein
• X is selected from the group consisting of , alkyl, substituted alkyl, sulfolamide, S0 2 alkyl, NHSO 2 , CH 2 , CH 2 CH 2 , SO 2 , CH 2 SO 2 , SO 2 CH 2 , OCH 2 CH 2 O, SO, CH 2 CH 2 SO, SOCH 2 CH 2 ; and wherein L, M and N are present or absent, and are selected from the group consisting of alkyl, NO 2 , halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO 2 H, CF 3 , aniline, nitro, heterocycle, mono-substituted alkyl, di- substituted alkyl, and tri-substituted alkyl, hydrogen, SO 2 NH 2 , SO 2 NH-alkyl, SOalkyl, NHSO 2 alkyl; wherein Y is selected from the group consisting of hydrogen, alkyl, substituted alky
• the compounds of the present invention have the structure:
• R 1 and R 5 are attached to any available carbon atom of phenyl rings A and B, respectively, and at each occurrence are independently selected from alkyl, substituted alkyl, halogen, cyano, nitro, OR 8 , NR 8 R 9 , C(O)R 8 , CO 2 R 8 , C(O)NR 8 R 9 , NR 8 C(O)R 9 , NR 8 C(O)OR 9 , S(O) 0 R 9 , NR 8 SO 2 R 9 , SO 2 NR 8 R 9 , cycloalkyl, heterocycle, aryl, and heteroaryl, and/or two OfR 1 and/or two of R 5 join together to form a fused benzo ring; R 2 , R 3 and R 4 are independently selected from hydrogen, alkyl, and substituted alkyl, or one of R 2 , R 3 and R 4 is
• Li further exemplary compounds, Z-R 6 taken together are selected from: i. thiophenyl optionally substituted with R 14 ; ii. imidazolyl optionally substituted with R 14 ; iii. ⁇ CH(aryl)(CO 2 C 1-6 alkyl); iv. -CO 2 -alkyl; v. -SO 2 -alkyl optionally substituted with up to three of halogen and/or phenyl; vi. -SO 2 -alkenyl optionally substituted with phenyl; and vii.
• R 17 is selected from alkyl, alkoxy, CO 2 C 1-6 alkyl, and SO 2 phenyl; and u and v are independently 0, 1 or 2.
• Other exemplary compounds have the following structure:
• R 17 is selected from alkyl, alkoxy, CO 2 C 1-6 alkyl, and S0 2 phenyl; and u and v are independently 0, 1 or 2.
• R 1 is selected from the group consisting of H, CN and SO 2 -piperidine
• R 2 is selected from the group consisting of H, 4-Cl-Ph, Ph, and 2-Me-imidazole
• R 3 is selected from the group consisting of H, CH 2 -2-imidazole, and CH2-2-oxazole.
• Other exemplary compounds have the following formula:
• R 1 is selected from the group consisting of H, 2,4-Cl 2 , 2-4-Me 2 , and 2,5-(CF 3 ) 2
• R 2 is selected from the group consisting of H, 4-Cl, 4-Me, 2,4-Cl 2 , 2,4-Me 2 , 3 -Cl
• X is selected from the group consisting of O and NH
• Y is selected from the group consisting of S, O, NCN, CO(3-CN-Ph), CO(4-CN-Ph), CO(4-Cl-Ph), and COEt.
• Particular exemplary compounds of the present invention include, but are not limited to:
• the compounds of the present invention may be provided with benzodiazepine related compounds as described in U.S. Patent Applications 10/886,450, 10/795,535, 10/634,114, 10/427,211, 10/217,878, 09/767,283, and 09/700,101; each herein incorporated by reference in their entireties.
• any one or more of these compounds can be used to treat a variety of dysregulatory disorders related to cellular death as described elsewhere herein. Additionally, any one or more of these compounds can be used to inhibit ATP Hydrolysis while not affecting cell synthesis or cell viability.
• any one or more of these compounds can be used in combination with at least one other therapeutic agent (e.g., potassium channel openers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, antiatherosclerotic agents, anticoagulants, antithrombotic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phospodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, antibacterial agents, antifungal agents,
• any one or more of these compounds can be used to treat a mitochondrial F 1 F 0 ATP hydrolase associated disorder (e.g., myocardial infarction, ventricular hypertrophy, coronary artery disease, non-Q wave MI, congestive heart failure, cardiac arrhythmias, unstable angina, chronic stable angina, Prinzmetal's angina, high blood pressure, intermittent claudication, peripheral occlusive arterial disease, thrombotic or thromboembolic symptoms of thromboembolic stroke, venous thrombosis, arterial thrombosis, cerebral thrombosis, pulmonary embolism, cerebral embolism, thrombophilia, disseminated intravascular coagulation, restenosis, atrial fibrillation, ventricular enlargement, atherosclerotic vascular disease, atherosclerotic plaque rupture, atherosclerotic plaque formation, transplant atherosclerosis, vascular remodeling atherosclerosis, cancer, surgery, inflammation, systematic infection, artificial surfaces, interventional
• compositions, formulations, and exemplary administration routes and dosing considerations Exemplary embodiments of various contemplated medicaments and pharmaceutical compositions are provided below.
• the compounds of the present invention are useful in the preparation of medicaments to treat a variety of conditions associated with dysregulation of cell death, aberrant cell growth and hyperproliferation.
• the compounds are also useful for preparing medicaments for treating other disorders wherein the effectiveness of the compounds are known or predicted.
• disorders include, but are not limited to, neurological (e.g., epilepsy) or neuromuscular disorders.
• the methods and techniques for preparing medicaments of a compound of the present invention are well-known in the art. Exemplary pharmaceutical formulations and routes of delivery are described below.
• any one or more of the compounds described herein, including the many specific embodiments, are prepared by applying standard pharmaceutical manufacturing procedures. Such medicaments can be delivered to the subject by using delivery methods that are well-known in the pharmaceutical arts.
• compositions are administered alone, while in some other embodiments, the compositions are preferably present in a pharmaceutical formulation comprising at least one active ingredient/agent, as defined above, together with a solid support or alternatively, together with one or more pharmaceutically acceptable carriers and optionally other therapeutic agents (e.g., a benzodiazepine compound as described in U.S. Patent Applications 10/886,450, 10/795,535, 10/634,114, 10/427,211, 10/217,878, 09/767,283, and 09/700,101; each herein incorporated by reference in their entireties.).
• Each carrier must be "acceptable” in the sense that it is compatible with the other ingredients of the formulation and not injurious to the subject.
• Contemplated formulations include those suitable oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary administration.
• formulations are conveniently presented in unit dosage form and are prepared by any method known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
• the formulations are prepared by uniformly and intimately bringing into association (e.g. , mixing) the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
• Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, wherein each preferably contains a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, hi other embodiments, the active ingredient is presented as a bolus, electuary, or paste, etc.
• tablets comprise at least one active ingredient and optionally one or more accessory agents/carriers are made by compressing or molding the respective agents
• compressed tablets are prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder ⁇ e.g., povidone, gelatin, hydroxypropylmetliyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose)surface-active or dispersing agent.
• a binder e.g., povidone, gelatin, hydroxypropylmetliyl cellulose
• lubricant e.g., inert diluent
• preservative e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose
• Molded tablets are made by molding in a suitable machine a mixture of the powdered compound (e.g., active ingredient) moistened with an inert liquid diluent. Tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
• Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
• compositions for topical administration are optionally formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils, hi alternatively embodiments, topical formulations comprise patches or dressings such as a bandage or adhesive plasters impregnated with active ingredient(s), and optionally one or more excipients or diluents.
• the topical formulations include a compound(s) that enhances absorption or penetration of the active agent(s) through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide (DMSO) and related analogues.
• DMSO dimethylsulfoxide
• the aqueous phase of a cream base includes, for example, at least about 30% w/w of a polyhydric alcohol, i. e. , an alcohol having two or more hydroxyl groups such as propylene glycol, butane- 1, 3 -diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
• a polyhydric alcohol i. e. , an alcohol having two or more hydroxyl groups such as propylene glycol, butane- 1, 3 -diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
• oily phase emulsions of this invention are constituted from known ingredients in an known manner.
• This phase typically comprises an lone emulsifier (otherwise known as an emulgent), it is also desirable in some embodiments for this phase to further comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
• a hydrophilic emulsifier is included together with a lipophilic emulsifier so as to act as a stabilizer. It some embodiments it is also preferable to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
• Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
• suitable oils or fats for the formulation is based on achieving the desired properties (e.g., cosmetic properties), since the solubility of the active compound/agent in most oils likely to be used in pharmaceutical emulsion formulations is very low.
• creams should preferably be a non-greasy, non-staining and washable products with suitable consistency to avoid leakage from tubes or other containers.
• Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the agent.
• a suitable carrier especially an aqueous solvent for the agent.
• Formulations for rectal administration may be presented as a suppository with suitable base comprising, for example, cocoa butter or a salicylate.
• Formulations suitable for vaginal administration may be presented as pessaries, creams, gels, pastes, foams or spray formulations containing in addition to the agent, such carriers as are known in the art to be appropriate.
• Formulations suitable for nasal administration include coarse powders having a particle size, for example, in the range of about 20 to about 500 microns which are administered in the manner in which snuff is taken, i.e., by rapid inhalation (e.g., forced) through the nasal passage from a container of the powder held close up to the nose.
• suitable formulations wherein the carrier is a liquid for administration include, but are not limited to, nasal sprays, drops, or aerosols by nebulizer, an include aqueous or oily solutions of the agents.
• Formulations suitable for parenteral administration include aqueous and non ⁇ aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
• the formulations are presented/formulated in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
• sterile liquid carrier for example water for injections
• Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
• Preferred unit dosage formulations are those containing a daily dose or unit, daily subdose, as herein above-recited, or an appropriate fraction thereof, of an agent.
• the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents. It also is intended that the agents, compositions and methods of this invention be combined with other suitable compositions and therapies.
• Still other formulations optionally include food additives (suitable sweeteners, flavorings, colorings, etc.), phytonutrients ⁇ e.g., flax seed oil), minerals ⁇ e.g., Ca, Fe, K, etc.), vitamins, and other acceptable compositions (e.g., conjugated linoelic acid), extenders, and stabilizers, etc.
• the compounds of the present invention are provided in unsolvated form or are in non-aqueous solutions (e.g., ethanol). The compounds may be generated to allow such formulations through the production of specific crystalline polymorphs compatible with the formulations.
• Such compositions and methods are described in U.S. Provisional Patent Application Serial No. 60/686,348, filed June 1, 2005, and herein incorporated by reference in its entirety.
• exemplary administration routes and dosing considerations Various delivery systems are known and can be used to administer therapeutic agents ⁇ e.g., exemplary compounds as described in Section III above) of the present invention, e.g., encapsulation in liposomes, microparticles, microcapsules, receptor- mediated endocytosis, and the like.
• Methods of delivery include, but are not limited to, intra-arterial, intra-muscular, intravenous, intranasal, and oral routes.
• the agents identified can be administered to subjects or individuals susceptible to or at risk of developing pathological growth of target cells and correlated conditions.
• the agent When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be added to a pharmaceutically acceptable carrier and systemically or topically administered to the subject.
• a tissue sample is removed from the patient and the cells are assayed for sensitivity to the agent.
• Therapeutic amounts are empirically determined and vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the agent. When delivered to an animal, the method is useful to further confirm efficacy of the agent.
• MLR-/pr mice develop systemic autoimmune disease.
• other animal models can be developed by inducing tumor growth, for example, by subcutaneously inoculating nude mice with about 10 5 to about 10 9 hyperproliferative, cancer or target cells as defined herein.
• the compounds described herein are administered, for example, by subcutaneous injection around the tumor. Tumor measurements to determine reduction of tumor size are made in two dimensions using venier calipers twice a week.
• Other animal models may also be employed as appropriate. Such animal models for the above-described diseases and conditions are well-known in the art.
• in vivo administration is effected in one dose, continuously or intermittently throughout the course of treatment.
• Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations are carried out with the dose level and pattern being selected by the treating physician.
• Suitable dosage formulations and methods of administering the agents are readily determined by those of skill in the art.
• the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
• the effective amount may be less than when the agent is used alone.
• the pharmaceutical compositions can be administered orally, intranasally, parenterally or by inhalation therapy, and may take the form of tablets, lozenges, granules, capsules, pills, ampoules, suppositories or aerosol form. They may also take the form of suspensions, solutions and emulsions of the active ingredient in aqueous or nonaqueous diluents, syrups, granulates or powders, hi addition to an agent of the present invention, the pharmaceutical compositions can also contain other pharmaceutically active compounds or a plurality of compounds of the invention.
• an agent of the present invention also referred to herein as the active ingredient
• the preferred route varies with the condition and age of the recipient, and the disease being treated.
• the agent should be administered to achieve peak concentrations of the active compound at sites of disease. This may be achieved, for example, by the intravenous injection of the agent, optionally in saline, or orally administered, for example, as a tablet, capsule or syrup containing the active ingredient.
• Desirable blood levels of the agent may be maintained by a continuous infusion to provide a therapeutic amount of the active ingredient within disease tissue.
• the use of operative combinations is contemplated to provide therapeutic combinations requiring a lower total dosage of each component antiviral agent than may be required when each individual therapeutic compound or drug is used alone, thereby reducing adverse effects.
• the present invention also includes methods involving co-administration of the compounds described herein with one or more additional active agents. Indeed, it is a further aspect of this invention to provide methods for enhancing prior art therapies and/or pharmaceutical compositions by co-administering a compound of this invention, hi co- administration procedures, the agents may be administered concurrently or sequentially, hi one embodiment, the compounds described herein are administered prior to the other active agent(s).
• the pharmaceutical formulations and modes of administration may be any of those described above.
• the two or more co-administered chemical agents, biological agents or radiation may each be administered using different modes or different formulations.
• the agent or agents to be co-administered depends on the type of condition being treated.
• the additional agent can be a chemotherapeutic agent or radiation.
• the additional agent can be an immunosuppressant or an anti- inflammatory agent.
• the additional agent can be an anti-inflammatory agent.
• the additional agents to be co ⁇ administered, such as anticancer, immunosuppressant, anti-inflammatory, and can be any of the well-known agents in the art, including, but not limited to, those that are currently in clinical use. The determination of appropriate type and dosage of radiation treatment is also within the skill in the art or can be determined with relative ease.
• Treatment of the various conditions associated with abnormal apoptosis is generally limited by the following two major factors: (1) the development of drug resistance and (2) the toxicity of known therapeutic agents.
• resistance to chemicals and radiation therapy has been shown to be associated with inhibition of apoptosis.
• Some therapeutic agents have deleterious side effects, including non-specific lymphotoxicity, renal and bone marrow toxicity.
• the methods described herein address both these problems. It is contemplated that drug resistance, where increasing dosages are required to achieve therapeutic benefit, is overcome by co-administering the compounds described herein with the known agent. It is contemplated that the compounds described herein sensitize target cells to known agents (and vice versa) and, accordingly, less of these agents are needed to achieve a therapeutic benefit.
• the sensitizing function of the claimed compounds also address the problems associated with toxic effects of known therapeutics.
• the known agent is toxic
• the claimed compounds when they are co-administered with the known agent, they reduce the dosage required which, in turn, reduces the deleterious effects.
• co-administration of proportionally more of these compounds than known toxic therapeutics will achieve the desired effects while minimizing toxic effects.
• the compounds of the present invention are screened for their binding affinity to the oligomycin sensitivity conferring protein (OSCP) portion of the mitochondrial ATP synthase complex.
• OSCP oligomycin sensitivity conferring protein
• compounds are selected for use in the methods of the present invention by measuring their biding affinity to recombinant OSCP protein.
• a number of suitable screens for measuring the binding affinity of drugs and other small molecules to receptors are known in the art.
• binding affinity screens are conducted in in vitro systems. In other embodiments, these screens are conducted in in vivo or ex vivo systems. While in some embodiments quantifying the intracellular level of ATP following administration of the compounds of the present invention provides an indication of the efficacy of the methods, preferred embodiments of the present invention do not require intracellular ATP or pH level quantification.
• Additional embodiments are directed to measuring levels (e.g., intracellular) of superoxide in cells and/or tissues to measure the effectiveness of particular contemplated methods and compounds of the present invention.
• levels e.g., intracellular
• assays and methods useful for measuring superoxide levels in cells and/or tissues will appreciate and be able to provide a number of assays and methods useful for measuring superoxide levels in cells and/or tissues.
• structure-based virtual screening methodologies are contemplated for predicting the binding affinity of compounds of the present invention with OSCP.
• compound structures are predicted from a molecular modeling software (e.g., MacroModel).
• Any suitable assay that allows for a measurement of the rate of binding or the affinity of an exemplary compound of the present invention to the OSCP may be utilized. Examples include, but are not limited to, competition binding using an exemplary compound, surface plasma resonance (SPR) and radio-immunopreciptiation assays (Lowman et al, J. Biol.Chem. 266:10982 [1991]).
• SPR surface plasma resonance
• radio-immunopreciptiation assays Lowman et al, J. Biol.Chem. 266:10982 [1991].
• Surface Plasmon Resonance techniques involve a surface coated with a thin film of a conductive metal, such as gold, silver, chrome or aluminum, in which electromagnetic waves, called Surface Plasmons, can be induced by a beam of light incident on the metal glass interface at a specific angle called the Surface Plasmon Resonance angle.
• Modulation of the refractive index of the interfacial region between the solution and the metal surface following binding of the captured macromolecules causes a change in the SPR angle which can either be measured directly or which causes the amount of light reflected from the underside of the metal surface to change. Such changes can be directly related to the mass and other optical properties of the molecules binding to the SPR device surface.
• biosensor systems based on such principles have been disclosed (See e.g., WO 90/05305).
• SPR biosensors e.g., BiaCore, Uppsala, Sweden.
• copmpounds are screened in cell culture or in vivo (e.g., non- human or human mammals) for an ability to modulate mitochondrial ATP synthase activity.
• Any suitable assay may be utilized, including, but not limited to, cell proliferation assays (Commercially available from, e.g., Promega, Madison, WI and Stratagene, La Jolla, CA) and cell based dimerization assays. (See e.g., Fuh et al, Science, 256: 1677 [1992]; Colosi et al, J. Biol. Chem., 268:12617 [1993]).
• Additional assay formats that find use with the present invention include, but are not limited to, assays for measuring cellular ATP levels, and cellular superoxide levels.
• the present invention also provides methods of modifying and derivatizing the compositions of the present invention to increase desirable properties (e.g., binding affinity, activity, and the like), or to minimize undesirable properties (e.g., nonspecific reactivity, toxicity, and the like).
• desirable properties e.g., binding affinity, activity, and the like
• undesirable properties e.g., nonspecific reactivity, toxicity, and the like.
• iterative design and chemical synthesis approaches are used to produce a library of derivatized child compounds from a parent compound.
• rational design methods are used to predict and model in silico ligand-receptor interactions prior to confirming results by routine experimentation.
• compositions of the present invention are contemplated to provide therapeutic benefits to patients suffering from any one or more of a number of conditions (e.g., diseases characterized by dysregulation of necrosis and/or apoptosis processes in a cell or tissue, disease characterized by aberrant cell growth and/or hyperproliferation, etc.) by modulating (e.g., inhibiting or promoting) the activity of the mitochondrial ATP synthase (as referred to as mitochondrial F 0 F 1 ATPase) complexes in affected cells or tissues.
• a number of conditions e.g., diseases characterized by dysregulation of necrosis and/or apoptosis processes in a cell or tissue, disease characterized by aberrant cell growth and/or hyperproliferation, etc.
• modulating e.g., inhibiting or promoting
• the activity of the mitochondrial ATP synthase as referred to as mitochondrial F 0 F 1 ATPase
• compositions of the present invention are used to treat autoimmune/chronic inflammatory conditions (e.g., psoriasis).
• compositions of the present invention are used in conjunction with stenosis therapy to treat compromised (e.g., occluded) vessels.
• stenosis therapy to treat compromised (e.g., occluded) vessels.
• the compositions of the present invention inhibit the activity of mitochondrial ATP synthase complex by binding to a specific subunit of this multi-subunit protein complex.
• compositions of the present invention bind to the oligomycin sensitivity conferring protein (OSCP) portion of the mitochondrial ATP synthase complex, to the OSCP/F1 junction, or to the Fl subunit.
• OSCP oligomycin sensitivity conferring protein
• the initial affect is overall inhibition of the mitochondrial ATP synthase complex, and that the downstream consequence of binding is a change in ATP or pH level and the production of reactive oxygen species (e.g., O 2 -).
• the present invention is not limited to any particular mechanism, nor to any understanding of the action of the agents being administered, it is contemplated that the generation of free radicals ultimately results in cell killing.
• the present invention is not limited to any particular mechanism, nor to any understanding of the action of the agents being administered, it is contemplated that the inhibiting mitochondrial ATP synthase complex using the compositions and methods of the present invention provides therapeutically useful inhibition of cell proliferation.
• preferred methods embodied in the present invention provide therapeutic benefits to patients by providing compounds of the present invention that modulate (e.g., inhibiting or promoting) the activity of the mitochondrial ATP synthase complexes in affected cells or tissues via binding to the oligomycin sensitivity conferring protein (OSCP) portion of the mitochondrial ATP synthase complex.
• OSCP oligomycin sensitivity conferring protein
• preferred embodiments of the present invention are directed to the discovery that many diseases characterized by dysregulation of necrosis and/or apoptosis processes in a cell or tissue, or diseases characterized by aberrant cell growth and/or hyperproliferation, etc., can be treated by modulating the activity of the mitochondrial ATP synthase complex including, but not limited to, by binding to the oligomycin sensitivity conferring protein (OSCP) component thereof.
• OSCP oligomycin sensitivity conferring protein
• the present invention is not intended to be limited, however, to the practice of the compositions and methods explicitly described herein. Indeed, those skilled in the art will appreciate that a number of additional compounds not specifically recited herein are suitable for use in the methods disclosed herein of modulating the activity of mitochondrial ATP synthase.
• the present invention thus specifically contemplates that any number of suitable compounds presently known in the art, or developed later, can optionally find use in the methods of the present invention.
• compounds including, but not limited to, oligomycin, ossamycin, cytovaricin, apoptolidin, bafilomyxcin, resveratrol, piceatannol, and dicyclohexylcarbodiimide (DCCD), and the like, find use in the methods of the present invention.
• DCCD dicyclohexylcarbodiimide
• the present invention is not intended, however, to be limited to the methods or compounds specified above, hi one embodiment, that compounds potentially useful in the methods of the present invention may be selected from those suitable as described in the scientific literature. (See e.g., K.B. Wallace and A. A.
• NCI-60 National Cancer Institute's
• compositions of the present invention are used to treat drug sensitive and/or drug resistant mycobacterium tuberculosis.
• compositions of the present invention are used in the treatment of angiogenesis.
• compositions of the present invention are used in the treatment of cardiovascular disease.
• compositions of the present invention are used in conjunction with stenosis therapy to treat compromised (e.g., occluded) vessels, hi further embodiments, it is contemplated that the compositions of the present invention are used in conjunction with stenosis therapy to treat compromised cardiac vessels.
• Vessel stenosis is a condition that develops when a vessel (e.g., aortic valve) becomes narrowed.
• aortic valve stenosis is a heart condition that develops when the valve between the lower left chamber (left ventricle) of the heart and the major blood vessel called the aorta becomes narrowed. This narrowing (e.g., stenosis) creates too small a space for the blood to flow to the body.
• the left ventricle pumps oxygen- rich blood to the body through the aorta, which branches into a system of arteries throughout the body.
• the 3 flaps, or leaflets, of the aortic valve open one way to allow blood to flow from the ventricle into the aorta. Between heartbeats, the flaps close to form a tight seal so that blood does not leak backward through the valve. If the aortic valve is damaged, it may become narrowed (stenosed) and blood flow may be reduced to organs in the body, including the heart itself.
• the long-term outlook for people with aortic valve stenosis is poor once symptoms develop. People with untreated aortic valve stenosis who develop symptoms of heart failure usually have a life expectancy of 3 years or less.
• Angioplasty involves inserting a balloon-tipped tube, or catheter, into a narrow or blocked artery in an attempt to open it. By inflating and deflating the balloon several times, physicians usually are able to widen the artery.
• Restenosis is the reclosure of a peripheral or coronary artery following trauma to that artery caused by efforts to open a stenosed portion of the artery, such as, for example, by balloon dilation, ablation, atherectomy or laser treatment of the artery.
• restenosis occurs at a rate of about 20-50% depending on the definition, vessel location, lesion length and a number of other morphological and clinical variables.
• Restenosis is believed to be a natural healing reaction to the injury of the arterial wall that is caused by angioplasty procedures. The healing reaction begins with the thrombotic mechanism at the site of the injury.
• the final result of the complex steps of the healing process can be intimal hyperplasia, the uncontrolled migration and proliferation of medial smooth muscle cells, combined with their extracellular matrix production, until the artery is again stenosed or occluded.
• metallic intravascular stents have been permanently implanted in coronary or peripheral vessels. The stent is typically inserted by catheter into a vascular lumen told expanded into contact with the diseased portion of the arterial wall, thereby providing mechanical support for the lumen.
• restenosis can still occur with such stents in place.
• the stent itself can cause undesirable local thrombosis.
• compositions of the present invention are eluted from drug-eluting stents in the treatment of compromised (e.g., occluded) vessels, hi further embodiments, the compositions of the present invention are eluted from drug-eluting stents in the treatment of compromised cardiac vessels.
• suitability considerations include, but are not limited to, the toxicity, safety, efficacy, availability, and cost of the particular compounds.
• compositions comprise compounds of the invention and, for example, therapeutic agents (e.g., antiatherosclerotic agents, anticoagulants, antithrombotic agents, antihypertensive agents, potassium channel openers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, ATPase inhibitors, mineralocorticoid receptor antagonists, phospodiesterase inhibitors, anti-inflammatory agents, antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, antibacterial agents, antifungal agents, cholesterol/lipid lowering agents and the like.
• Antihypertensive agents include, but are not limited to, ACE inhibitors, AT-I receptor antagonists, ET receptor antagonists, dual ET/ All receptor antagonists, and vasopepsidase inhibitors, or an antiplatelet agent selected from GP ⁇ b/IIIa blockers, P2Yi and P2Y 12 antagonists, thromboxane receptor antagonists, and aspirin.
• the compounds of the present invention are useful in treating a mitochondrial F 1 F 0 ATP hydrolase associated disorder (e.g., myocardial infarction, ventricular hypertrophy, coronary artery disease, non-Q wave MI, congestive heart failure, cardiac arrhythmias, unstable angina, chronic stable angina, Prinzmetal's angina, high blood pressure, intermittent claudication, peripheral occlusive arterial disease, thrombotic or thromboembolic symptoms of thromboembolic stroke, venous thrombosis, arterial thrombosis, cerebral thrombosis, pulmonary embolism, cerebral embolism, thrombophilia, disseminated intravascular coagulation, restenosis, atrial fibrillation, ventricular enlargement, atherosclerotic vascular disease, atherosclerotic plaque rupture, atherosclerotic plaque formation, transplant atherosclerosis, vascular remodeling atherosclerosis, cancer, surgery, inflammation, systematic infection, artificial surfaces, intervention
• the mitochondrial permeability transition pore is a pore that spans the inner and outer mitochondrial membrandes and functions in the regulation of proapoptotic particles. Transient MPTP opening results in the release of cytochrome c and the apoptosis inducing factor from the mitochondrial intermembrane space, resulting in cellular apoptosis.
• the oligomycin sensitivity conferring protein is a subunit of the F 0 F 1 mitochondrial ATP synthase/ ATPase and functions in the coupling of a proton gradient across the Fo sector of the enzyme in the mitochondrial membrane, hi preferred embodiments, it is contemplated that compounds of the present invention bind the OSCP, the OSCP / Fl junction, or the Fl subunit, increases superoxide and cytochrome c levels, increases cellular apoptosis, and inhibits cellular proliferation.
• the adenine nucleotide translocator is a 3OkDa protein that spans the inner mitochondrial membrane and is central to the mitochondrial permeability transition pore (MPTP).
• Thiol oxidizing or alkylating agents are powerful activators of the MPTP that act by modifying one or more of three unpaired cysteines in the matrix side of the ANT. 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide, inhibits the ANT.
• Epidermal hyperplasia e.g., excessive keratinocyte proliferation leading to a significant thickening of the epidermis in association with shedding of the thickened epidermis
• psoriasis see, e.g., Krueger GC, et al., (1984) J. Am. Acad. Dermatol. 11 : 937-947; Fry L. (1988), Brit. J. Dermatol. 119:445-461 ; each herein incorporated by reference in their entireties
• physiological conditions e.g., during wound-healing.
• the central role of the EGF receptor in regulating hyperplastic epithelial growth makes the EGF receptor tyrosine kinase a target for antiproliferative agents.
• the series of signaling molecules engaged downstream of this receptor are additional points at which keratinocyte growth can be interrupted.
• MAPK MAPK cascade
• EGF receptor see, e.g., Marques, S. A., et al., (2002) J Pharmacol Exp Ther 300, 1026-1035; herein incorporated by reference in its entirety
• hi hyperproliferative epidermis, but not in normal epidermis, extracellular signal-regulated kinases 1/2 (Erk 1/2) are activated in basal and suprabasal keratinocytes and contribute to epidermal hyperproliferation (see, e.g., Haase, L, et al., (2001) J Clin Invest 108, 527-536; Takahashi, H., et al., (2002) J Dermatol Sci 30, 94-99; each herein incorporated by reference in their entireties), hi culture models, keratinocyte growth regulation through the EGF receptor results in increased MAPK activity.
• growth factor- stimulated MAPK activity is also dependent on integrin engagement and extracellular matrix molecules that bind integrins are capable of independently activating MAPKs and increasing keratinocyte proliferation (see, e.g., Haase, L, et al., (2001) J Clin Invest 108, 527-536; herein incorporated by reference in its entirety).
• the proliferation of other skin cells, including fibroblasts is less dependent on Erk 1/2 activity, making Erk inhibition a potentially useful characteristic to evaluate lead compounds for potential utility against epidermal hyperplasia.
• compounds of the present invention are useful for treating epidermal hyperplasias.
• Psoriasis is common and chronic epidermal hyperplasia.
• Plaque psoriasis is the most common type of psoriasis and is characterized by red skin covered with silvery scales and inflammation. Patches of circular to oval shaped red plaques that itch or burn are typical of plaque psoriasis. The patches are usually found on the arms, legs, trunk, or scalp but may be found on any part of the skin. The most typical areas are the knees and elbows. Psoriasis is not contagious and can be inherited.
• psoriasis treatments for psoriasis includes topical steroids, coal tar, keratolytic agents, vitamin
• Topical steroids are agents used to reduce plaque formation. Topical steroid agents have anti-inflammatory effects and may cause profound and varied metabolic activities. In addition, topical steroid agents modify the body's immune response to diverse stimuli. Examples of topical steroids include, but are not limited to, triamcinolone acetonide (Artistocort, Kenalog) 0.1% cream, and betamethasone diproprionate (Diprolene, Diprosone) 0.05% cream.
• Coal tar is an inexpensive treatment available over the counter in shampoos or lotions for use in widespread areas of involvement. Coal tar is particularly useful in hair-bearing areas.
• coal tar is coal tar 2-10% (DHS Tar, Doctar, Theraplex T) - antipruitic.
• Keratolytic agents are used to remove scale, smooth the skin, and to treat hyperkeratosis.
• An example of a keratolytic agent is anthralin 0.1-1% (Drithocreme, Anthra-Derm).
• Vitamin D-3 analogs are used in patients with lesions resistant to older therapy or with lesions on the face or exposed areas where thinning of the skin would pose cosmetic problems.
• An example of a vitamin D-3 analog is calcipotriene (Dovonex).
• Topical retinoids are agents that decrease the cohesiveness of follicular epithelial cells and stimulate mitotic activity, resulting in an increase in turnover of follicular epithelial cells.
• topical retinoids include, but are not limited to, tretinoin (Retin-A, Avita), and tazarotene (Tazorac).
• tretinoin Retin-A, Avita
• Tazorac tazarotene
• plaque psoriasis can evolve into more severe disease, such as pustular psoriasis or erythrodermic psoriasis, hi pustular psoriasis, the red areas on the skin contain blisters with pus.
• hi erythrodermic psoriasis a wide area of red and scaling skin is typical, and it may be itchy and painful.
• the present invention is useful in treating additional types of psoriasis, including but not limited to, guttate psoriasis, nail psoriasis, inverse psoriasis, and scalp psoriasis.
• the compounds of the present invention are useful in treating pigmentation disorders (e.g., albinism, melasma, and vitiligo).
• the present invention is not limited to a particular mechanism for treating pigment disorders.
• pigment disorders are treated through targeting of the F 1 F 0 -ATPaSe by the compounds of the present invention, hi further embodiments, pigment disorders are treated through the rerouting of tyrosinase by the compounds of the present invention, hi further embodiments, pigment disorders are treated through targeting of prohibitin by the compounds of the present invention.
• the present invention provides compounds that are contemplated to target the F 1 F 0 - ATPase.
• the present invention provides compounds that are contemplated to target the F 1 F 0 -ATPaSe as a treatment for autoimmune disorders, and in particular, compounds with low toxicity.
• the present invention further provides methods of identifying compounds that are contemplated to target the F 1 F 0 -ATPaSe.
• the present invention provides therapeutic applications for compounds contemplated to target the F 1 F 0 -ATPaSe.
• a majority of ATP within eukaryotic cells is synthesized by the mitochondrial F 1 F 0 - ATPase (see, e.g.,C. ⁇ . Gregory et ah, J. Immunol., 139:313-318 [1987]; J.P. Portanova et aL, MoI. Immunol., 32:117-135 [1987]; MJ. Shlomchik et ah, Nat. Rev. Immunol, 1:147- 153 [2001]; each herein incorporated by reference in their entireties).
• the mitochondrial F 1 F 0 -ATPaSe is composed of three major domains: F 0 , F 1 and the peripheral stator.
• F 1 is the portion of the enzyme that contains the catalytic sites and it is located in the matrix ⁇ see, e.g., Boyer, PD, Annu Rev Biochem.1997; 66:717-49; herein incorporated by reference in its entirety). This domain is highly conserved and has the subunit composition ⁇ 3 ⁇ 3 ⁇ .
• the landmark X-ray structure of bovine F 1 revealed that ⁇ 3 ⁇ 3 forms a hexagonal cylinder with the ⁇ subunit in the center of the cylinder.
• F 0 is located within the inner mitochondrial membrane and contains a proton channel. Translocation of protons from the inner-membrane space into the matrix provides the energy to drive ATP synthesis.
• the peripheral stator is composed of several proteins that physically and functionally link F 0 with F 1 .
• the stator transmits conformational changes from F 0 into in the catalytic domain that regulate ATP synthesis ⁇ see, e.g., Cross RL, Biochim Biophys Acta 2000; 1458:270-75; herein incorporated by reference in its entirety).
• Mitochondrial F 1 F 0 -ATPaSe inhibitors are invaluable tools for mechanistic studies of the F 1 F 0 -ATPaSe ⁇ see, e.g., James AM, et al, J Biomed Sci 2002; 9:475-87; herein incorporated by reference in its entirety). Because F 1 F 0 -ATPaSe inhibitors are often cytotoxic, they have been explored as drugs for cancer and other hyperproliferative disorders.
• Macrolides ⁇ e.g., oligomycin and apoptolidin
• Macrolides bind to F 0 which blocks proton flow through the channel resulting in inhibition of the F 1 F 0 - ATPase.
• macrolides have an unacceptably narrow therapeutic index and are highly toxic ⁇ e.g., the LD 5 Q for oligomycin in rodents is two daily doses at 0.5 mg/kg) ⁇ see, e.g., Kramar R, et al, Agents & Actions 1984, 15:660-63; herein incorporated by reference in its entirety). It is contemplated that inhibitors OfF 1 F 0 -ATPaSe include the compounds of the present invention.
• state 4 In cells that are actively respiring (known as state 3 respiration), inhibiting F 1 F 0 - ATPase blocks respiration and places the mitochondria in a resting state (known as state 4).
• state 4 the MRC is reduced relative to state 3, which favors reduction of O 2 to O 2 " at complex III ⁇ see, e.g., N. Zamzami et al, J. Exp. Med., 181:1661-1672 [1995]; herein incorporated by reference in its entirety).
• treating cells with either oligomycin or, it is contemplated, compounds of the present invention leads to a rise of intracellular O 2 " as a consequence of inhibiting complex V.
• F 1 F 0 -ATPaSe inhibitors are either toxic (e.g., oligomycin) or, it is contemplated, therapeutic (e.g., compounds of the present invention).
• the present invention provides a method of distinguishing toxic F 1 F 0 -ATPaSe inhibitors from therapeutic F 1 F 0 -ATPaSe inhibitors.
• F 1 F 0 -ATPaSe inhibitors with therapeutic potential e.g., compounds of the present invention
• F 1 F 0 -ATPaSe inhibitors with therapeutic potential present a novel mode of inhibition.
• F 1 F 0 -ATPaSe inhibitors with beneficial properties are uncompetitive inhibitors that only bind enzyme-substrate complexes at high substrate concentration and do not alter the k cat /K m ratio. This knowledge forms the basis to identify and distinguish F 1 F 0 -ATPaSe inhibitors with therapeutic potential from toxic compounds.
• the present invention provides compounds that are contemplated to target the F 1 F 0 - ATPase as an autoimmune disorder treatment.
• the present invention provides methods of identifying compounds that target the F 1 F 0 -ATPaSe while not altering the k cat /Km ratio.
• the present invention provides therapeutic applications for compounds targeting the F 1 F 0 -ATPaSe.
• the present invention provides compounds that are contemplated to inhibit the F 1 F 0 - ATPase. Jn some embodiments, it is contemplated that the compounds do not bind free F 1 F 0 - ATPase, but rather bind to an F 1 F 0 - ATPase-substrate complex. It is contemplated that the compounds show maximum activity at high substrate concentration and minimal activity (e.g., F 1 F 0 -ATPaSe inhibiting) at low substrate concentration. In preferred embodiments, it is contemplated that the compounds do not alter the k cat /K m ratio of the F 1 F 0 -ATPaSe.
• the properties of the F 1 F 0 -ATPaSe inhibitors of the present invention are in contrast with oligomycin, which is a F 1 F 0 -ATPaSe inhibitor that is acutely toxic and lethal.
• Oligomycin is a noncompetitive inhibitor, which binds to both free F 1 F 0 -ATPaSe and F t F o -ATPase-substrate complexes and alters the k ca t/K m ratio.
• the present invention provides methods of identifying (e.g., screening) compounds useful in treating autoimmune disorders.
• the present invention is not limited to a particular type compound.
• compounds of the present invention include, but are not limited to, pharmaceutical compositions, small molecules, antibodies, large molecules, synthetic molecules, synthetic polypeptides, synthetic polynucleotides, synthetic nucleic acids, aptamers, polypeptides, nucleic acids, and polynucleotides.
• the present invention is not limited to a particular method of identifying compounds useful in treating autoimmune disorders.
• compounds useful in treating autoimmune disorders are identified as possessing an ability to inhibit an F 1 F 0 -ATPaSe while not altering the k cat /K m ratio.
• the present invention provides methods for treating disorders (e.g., neurodegenerative diseases, Alzheimers, ischemia reprofusion injury, neuromotor disorders, non-Hodgkin's lymphoma, lymphocytic leukemia, cutaneous T cell leukemia, an autoimmune disorder, cancer, solid tumors, lymphomas, leukemias, and tuberculosis).
• disorders e.g., neurodegenerative diseases, Alzheimers, ischemia reprofusion injury, neuromotor disorders, non-Hodgkin's lymphoma, lymphocytic leukemia, cutaneous T cell leukemia, an autoimmune disorder, cancer, solid tumors, lymphomas, leukemias, and tuberculosis.
• disorders e.g., neurodegenerative diseases, Alzheimers, ischemia reprofusion injury, neuromotor disorders, non-Hodgkin's lymphoma, lymphocytic leukemia, cutaneous T cell leukemia, an autoimmune disorder, cancer, solid tumors, lymphomas, leukemias
• cell inhibition includes, but is not limited to, cell growth prevention, cell proliferation prevention, and cell death.
• inhibition of a target cell is accomplished through contacting a target cell with a compound contemplated to inhibit the F 1 F 0 -ATPaSe.
• target cell inhibition is accomplished through targeting of the F 1 F 0 -ATPaSe with a compound contemplated to inhibit the F 1 F 0 - ATPase.
• the present invention is not limited to a particular F 1 F 0 -ATPaSe inhibitor.
• the F 1 F 0 -ATPaSe inhibitor is contemplated to possess an ability to inhibit an F 1 F 0 -ATPaSe while not altering the k cat /K m ratio.
• the present invention further provides methods for selectively inhibiting the pathology of target cells in a subject in need of therapy.
• the present invention is not limited to a particular method of inhibition target cell pathology.
• target cell pathology is inhibited through administration of an effective amount of a compound of the invention.
• the present invention is not limited to a particular compound.
• the compound is an F 1 F 0 - ATPase inhibitor.
• the compound inhibits the F 1 F 0 -ATPaSe while not altering the k cat /K m ratio.
• R was H, NH 2 , or nicotinic.
• Cells in log-phase growth were collected by centrifugation (300 g, 5 min), exchanged into fresh media (containing 1% or 0.2% FBS), and diluted to a concentration between 100,000 and 300,000 cells/mL. Drugs were added from 50x stocks, and the cells cultured (37 °C, 5% CO 2 ) for 24 h prior to analysis. Cells were analyzed by the MTT dye conversion assay to determine relative cell number/viability, and by flow cytometry to enumerate cell viability.
• the mechanism of inhibition for ATP hydrolysis induced by Bz-423 and derivatives of Bz-423 was assayed using an NADH-coupled assay.
• the ATP hydrolytic activity of the sub-mitochondrial particles (hereinafter SMPs) was measured by coupling the production of ADP to the oxidation of NADH via the pyruvate kinase and lactate dehydrogenase reaction. Briefly, ATP hydrolysis SMPs (0.8 mg; 7.14 ⁇ g/well) were added to hydrolysis buffer (100 mM Tris-HCL pH 8.0 at 25°C, 4 mM MgCl 2 , 50 mM EDTA, 0.2 niM EDTA) and vortexed.
• hydrolysis buffer 100 mM Tris-HCL pH 8.0 at 25°C, 4 mM MgCl 2 , 50 mM EDTA, 0.2 niM EDTA
• 125 ⁇ L of this suspension was added to each well of a 96-well plate containing 50x drug or DMSO vehicle control (1% DMSO, final).
• the 96-well plate was then placed at 30°C in a Molecular Devices Versamax tunable microplate reader and allowed to incubate for 5 min.
• a substrate-coupling mixture was prepared (containing X rnM ATP, 0.2 mM NADH, 1 mM phosphoenolpyruvate (PEP), 2 U/mL pyruvate kinase (PK), and 2 LVmL lactate dehydrogenase (LDH) in hydrolysis buffer).
• V 0 V max [S] / ((1+ [I] / K0K m + [S])
• V 0 V max [S] / ((1+ [I] / Ki*) [S] + K 1n )
• V 0 V max [S] / ((1+ [I]/Ki)K m + (1+ [W)[S])

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=36036988

Family Applications (1)

Country Status (8)

Cited By (3)

Families Citing this family (40)

Family Cites Families (83)

• 2004
  • 2004-09-07 US US10/935,333 patent/US20050113460A1/en not_active Abandoned
• 2005
  • 2005-09-07 JP JP2007531319A patent/JP2008512477A/ja active Pending
  • 2005-09-07 EP EP11173231A patent/EP2422788A3/en not_active Withdrawn
  • 2005-09-07 WO PCT/US2005/031942 patent/WO2006029245A2/en active Application Filing
  • 2005-09-07 AU AU2005282461A patent/AU2005282461C1/en not_active Ceased
  • 2005-09-07 CN CN2005800363803A patent/CN101048162B/zh not_active Expired - Fee Related
  • 2005-09-07 CN CN2011103284209A patent/CN102512424A/zh active Pending
  • 2005-09-07 EP EP05804417A patent/EP1786429A4/en not_active Withdrawn
  • 2005-09-07 CA CA002579567A patent/CA2579567A1/en not_active Abandoned
  • 2005-09-07 US US11/662,103 patent/US20080293700A1/en not_active Abandoned
• 2007
  • 2007-03-06 IL IL181754A patent/IL181754A0/en unknown
• 2012
  • 2012-03-07 IL IL218524A patent/IL218524A0/en unknown
  • 2012-06-14 JP JP2012134937A patent/JP2012197305A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events